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1.  THESIS ABSTRACT 
 
Increasingly patients are surviving admission to intensive care units (ICUs) with life-
threatening, critical illness. This has led to a growing interest in longer-term patient 
outcomes, including their psychological health. 
 
This thesis consists of two discrete sections: 1) a systematic review of research that 
evaluated emotional outcomes between 3 and 12 months post-ICU discharge, and 2) 
a longitudinal cohort study of emotional sequelae among adults with Type 1 diabetes 
during and following admission for diabetic ketoacidosis (DKA).   
 
The systematic review identified seven studies that met inclusion criteria, and 
highlighted weaknesses in the existing literature. From the available evidence there 
appears to be elevated rates of clinically significant depression (11%), anxiety (15%) 
and post-traumatic stress disorder (PTSD) symptoms (23%) 3 months after 
discharge, and these remain high 9 months later (12%; 18%, and 27%, respectively).  
 
The prospective study of DKA admissions indicated substantial rates of clinically 
relevant depression (25%); anxiety (37.5%), and PTSD symptoms (37.5%) prior to 
discharge. However, 3 months later the rates of depression and PTSD had 
substantially attenuated (both 8.3%) although rates of anxiety (37.5%) remained 
higher than that found in the general population (7%) and the local Type 1 diabetes 
clinical community (11.9%). Those admitted with DKA had significantly poorer 
HbA1c compared to the overall Type 1 clinic population (10.9% vs. 8.9%; p < 
0.0001), which indicates substantial difficulties in self managing their condition.   
 
It appears that psychological problems are elevated over time following ICU 
discharge. PTSD is notably high and enduring in general ICU survivors, whereas was 
observed to fall away in the DKA sample. Anxiety seems to be elevated and this 
persists over time following DKA; this is pertinent given the dearth of research on 
the role of anxiety in the efforts of people with type 1 diabetes to manage their 
condition.  As far as the authors’ are aware, this is the first study tracking emotional 
2 
 
outcomes post DKA discharge. There are clearly significant psychological issues that 
will likely impact on staff efforts to provide ward-based care aimed at improving 
post-discharge diabetes control, and on the future efforts of those admitted for DKA 
to self-manage a complex condition. A greater awareness of the psychological issues  
affecting people with type 1 diabetes who experience DKA is an important first step. 
More specifically, a better understanding among health professionals about the ways 
emotional distress can impact on self-management is needed, as well as a greater 
understanding of how best to communicate information and educational material in 
light of possible information processing deficits (which may be a result of emotional 
distress). Larger, multi-centre, higher quality studies are required in both general 
ICU settings and looking at specific disease complications (such as DKA). 
Psychological screening for ICU survivors and implementation of a care pathway to 




2. THESIS OVERVIEW  
 
This thesis consists of a systematic review of research that evaluated psychological 
outcomes between 3 and 12 months post-ICU discharge. This review has been 
presented in the format required by the journal, Journal of Critical Care. A bridging 
chapter then introduces the quantitative research project. The methods of this 
research project are described in detail. This is a prospective longitudinal cohort 
study of emotional sequelae among adults with Type 1 diabetes during and following 
admission for DKA. It is provided as a journal article, in the format required by 
Diabetes Care. The guidelines for submissions to both journals are included in 
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To systematically review studies evaluating the emotional outcome of Intensive Care 
Unit (ICU) survivors between 3 and 12 months post-discharge. 
 
Methods 
A systematic review was performed using Medline, EMBASE, CINAHL and 
PsycINFO. Reference lists from all included studies were also screened.  
 
Results 
Seven articles met eligibility criteria. The mean scores at baseline were below case 
levels for anxiety and depression (7.23 and 6.30 in the Hospital Anxiety and 
Depression Scale, respectively) and at 6 months were again non-case levels for 
anxiety, depression and post-traumatic stress disorder (PTSD) respectively. The 
mean clinical caseness for anxiety, depression and PTSD symptoms were 15%, 11% 
and 23% at 3 months and 18%, 12% and 27% at 12 months respectively. No 
significant change over time was observed for levels of emotional distress in the 
majority of studies.  
 
Conclusions 
The acute stress reaction typically reported following non-ICU traumatic events up to 
3 months was not observed, however emotional distress does not appear to attenuate 
from 1 to 12 month follow-up and the reasons for this are unclear. Although larger, 
multi-centre, higher quality studies are needed, as well as a widely-accepted 
methodological quality criterion, it is apparent that ICU survivors require both 
psychological and physical care. 
 
Keywords 




3.1  Introduction 
Many adults are admitted to intensive care units (ICUs) throughout the UK every 
year. For example, there have been about 35,000 admissions per year to ICUs in 
Scotland over the past decade or so [1]. The presenting nature of critical illness to 
ICU is heterogeneous, however, always life-threatening [2]. Abnormalities in 
respiratory rate and suctioning pain are commonplace, as well as hypothalamic-
pituitary-adrenal strain and circadian rhythm sleep disorder [2].  
 
Regular physiological observations of patients are required and this can frequently 
include invasive monitoring of heart rate, oxygen saturation and temperature [2]. 
Sedation for pain alleviation is routine and various invasive or interventional 
procedures are carried out while patients are in critical care, including mechanical 
ventilation and emergency surgical procedures [2]. Patients often have limited ability 
to communicate; experience loss of control of their bodily functions; suffer periods 
of impaired cognition (including confusion and delirium), and reduced autonomy 
during and after administration of these treatments [2]. Moreover, a patient 
experiencing some or all of these symptoms may likely have difficulties interacting 
with staff and visitors, which has been demonstrated to increase frustration and 
perceived isolation [3].  
 
The numbers of people surviving admission to ICUs continues to improve. In the last 
decade, the inpatient mortality rate has decreased from about 33% to 25% [1]. For 
many patients recuperation is relatively uncomplicated but for others, discharge from 
ICU is the start of an uncertain journey towards recovery. Recovery from illness is 
highly individual, and few studies have been able to demonstrate a close relationship 
between specific features of an acute illness and its longer-term impact [4]. As one 
may expect, patients who have had more prolonged episodes of critical illness are 
likely to have greater long-term difficulties [4], however, patients with even 
relatively short ICU stays may also need substantial help. Whilst many patients 
recover to previous levels of functioning [5], some patients experience persistent 
problems or develop new difficulties after their ICU stay, which can impact on many 
aspects of their life. In short, life may change in profound ways for ICU survivors. 
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For example, often survivors have to reduce their hours of employment or give up 
their jobs due to physical limitations and this will impact on their economic situation 
[5]. Moreover, some may become dependent on others to carry out activities of daily 
living which may fundamentally alter their relationships with family and friends [5, 
6].  
 
Traditionally, rehabilitation after ICU focussed on physical functioning [4] because 
physical weakness and reduced mobility are commonplace after prolonged intensive 
care [2]. However, over recent times there has been an increasing focus on 
psychological outcomes, which in part reflects a greater emphasis within healthcare 
of holistic, person-centred care. Emerging research suggests that the ICU experience 
itself and the combined post-discharge effects of critical illness can have a negative 
impact on emotional wellbeing, quality of life and neuropsychological outcomes 
[7,8] . Previous systematic reviews cite median point prevalence rates of 28% (range 
8 to 57%) for depression (1 to 21 months post discharge) [9], and 22% (range 0 to 
62%) for post traumatic stress disorder (PTSD; 2-120 months post discharge) [10], 
experienced by patients following ICU admission.  
 
Recently, researchers have become increasingly interested in PTSD and PTSD 
symptoms post-ICU discharge [10]. PTSD is characterised by a triad of symptoms 
(internally re-experiencing the traumatic event; avoidance of situations that are 
associated with the traumatic event, and hyper-arousal of the autonomic nervous 
system) causing significant distress and impairment in day-to-day functioning. 
Although the potential for a post-traumatic psychological reaction following critical 
illness is not in doubt, it is important that rather than focusing on a single mental 
health condition, researchers and clinicians are mindful of emotional distress in a 
broader sense [11]. This is partly because it is widely known that approximately 80% 
of PTSD cases arise in the context of clinically significant co-morbid psychological 
problems [12]. Most commonly, anxiety disorders and depression co-occur with 
PTSD (in about 55% and 50% of cases, respectively [12]). There is also debate about 
the validity of differentiating among these clinical diagnoses due to significant 
symptom overlap. For example, diminished interest in previously enjoyable activities 
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and sleep difficulties are symptoms of both PTSD and depression; whereas 
irritability and hyper-vigilance are indicators of PTSD and other anxiety disorders 
[12,13,14].  It is also important to note that both anxiety and depression can 
commonly occur after trauma without PTSD or with sub-clinical levels of PTSD 
symptoms [12].Although there have been systematic reviews of depression and of 
PTSD symptoms in patients following ICU discharge, there are many limitations to 
this research. Importantly, the vast heterogeneity of populations studied means it is 
very difficult for the reader to make valid or reliable conclusions. For example, one 
review [10] compares a general ICU in Turkey two months post discharge with a 
sample in Sweden of medical trauma admissions 118 months post discharge. In this 
systematic review the authors’ wanted to look at the same samples admitted to 
general ICU across time so they acted as their own controls and to enable the course 
of clinical caseness to be clearer. Furthermore, a minimum of three months follow-up 
was imposed in order to reduce the likelihood of any acute reaction skewing the 
results (which is typically seen in general trauma literature [14]). Studies which 
reported PTSD and anxiety and depression were reviewed over time in order to see if 
there is a possibility of symptom overlap. As far as the authors’ are aware there has 
been no systematic review exploring more generally the emotional outcomes 
(defined as PTSD and anxiety and depression herein) of this group. Therefore, the 
aim of this review is to evaluate systematically the symptoms of PTSD, anxiety, and 
depression among ICU survivors between 3 and 12 months post-discharge.  
 
3.2  Methods 
3.2.1  Search strategy 
The main search to identify relevant studies was conducted in July (week 23) of 
2012. The Cochrane Library was searched to identify any previous systematic 
reviews of emotional distress encompassing PTSD symptoms, anxiety and 
depression measures; none were identified. 
 
The following databases were then searched using EBSCOhost: Medline (2000- 
week 29 2012); EMBASE (2000- week 29 2012); CINAHL (2000- week 29 2012); 




The search strategy included the following terms mapped to the appropriate 
keywords (“Stress, Disorders Post-Traumatic” OR “anxiety” OR “depression”) AND 
(“critical care” OR “intensive care units” OR “intensive care”). The search boxes 
“English language” and “human” were also ticked. 
 
3.2.2  Study selection 
Articles were selected for review if they met all of the following criteria:- 
• The study population was composed of an adult (≥18 years) ICU population. 
• PTSD and anxiety and depression assessments were conducted using validated 
measures at a minimum of 3 months and maximum of 12 month follow-up post 
ICU discharge. 
• The study was published in English. 
 
Unpublished articles were not included. In addition, studies reporting on the 
following conditions/events were also excluded: transplants, natural disasters, 
physical trauma populations in isolation (including RTA/ burns), war veterans, 
chronic pain, Guillain-Barre Syndrome, pregnancy / post-partum, elective surgery, 
cancers and neurological conditions such as stroke and brain injury.  
 
One rater (KYM), sequentially reviewed citations, abstracts and full-text articles to 
select eligible studies. Reference lists from all included studies were screened by the 
reviewer to search for further papers. 
 
3.2.3  Data abstraction  
For each eligible study, information was abstracted regarding characteristics of the 
study cohorts, PTSD, anxiety, and depression measures. Authors of eligible studies 
were contacted for additional information, when necessary. The mean prevalence 
rates of clinically significant levels (or caseness) for anxiety; depression and PTSD 
were calculated and plotted. Hospital Anxiety and Depression Scale (HADS; 15) 
anxiety or depression scores of 11 or greater were considered as clinical cases. This 
conservative threshold is a deviation from other authors' recommendations [e.g. 16], 
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and although it may reduce the sensitivity, it reduced the likelihood of inflated 
prevalence rates and is in keeping with standard clinical practice.  A linear trend line 
was also plotted to explore levels of clinical caseness post-ICU. One of the main 
ways PTSD differs from other anxiety disorders is that for most people it is often 
characterised by a progressive reduction of symptoms over time. One area where 
there has been significant research and an extreme PTSD course is rape and 
therefore, for reference, the rate of PTSD symptoms following rape [17] was plotted. 
Absolute numbers of those meeting clinical levels of PTSD, anxiety and depression 
were reported. In one article, data was drawn from the control group of randomised 
controlled trials (RCTs).  
 
3.2.4  Methods of reviewing studies 
We have discriminated between reporting and methodological quality as proposed by 
da Costa [18].  
 
Reporting quality herein is defined as “the completeness with which a study is 
presented and whether major items for the proper appraisal of internal and external 
validity of findings are clearly reported” (Williams, 2010). The Strengthening in 
Reporting of Observational Studies in Epidemiology [STROBE; 19; further detail in 
Appendix 3] statement is used to assess the reporting quality.  
 
Methodological quality herein refers to the “appropriateness of the methods 
employed in the design and conduct of epidemiological research, which determines 
the reliability of findings” [18]. A wide range of methodological quality criteria were 
considered however many were neither valid nor reliable for observational studies 
[e.g. 20, 21, 22]. From the literature [e.g. 23, 24], expert opinion (Cochrane 
Collaboration Bias Group) and personal communication with the authors of previous 
systematic reviews (personal communications, 18 January 2012) in field there 
appears to be no consensus or standardised methodological quality criteria of 
observational studies. Therefore in this study key methodological components 
impacting the systematic review question are discussed and critically appraised 
within the results section which is consistent with a recent systematic review of 
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observational studies stating that studies should be considered based on individual 
quality components [23] rather than on summary scores which involve inherent 
weighting of component items which have been deemed both variable and 
inconsistent [24]. 
 
The raters (KYM and AK) calculated inter-observer agreement for data abstraction 
using intra-rater co-efficient. In addition mean scores of anxiety, depression and post 
PTSD were collated from the studies or additional information from the authors. 
 
3.3  Results 
3.3.1  Search results  
Appendix 4 details the search results from each database. As illustrated in Figure 3.1, 
the full texts of 45 studies were evaluated independently by two raters (the first and 
second authors). There was 100% inter-rater agreement that eight articles were 
eligible for data abstraction. One article [25] used a total score for the HADS and the 
authors did not respond to requests for individual anxiety and depression scale 







































































Fig. 3.1  Flowchart of study selection 
 
1,572 reports excluded based on title review:- 
 
- 669 duplicate files across databases 
- 903 not applicable based on title reviews 
409 reports retrieved for evaluation of abstract 
364 Reports excluded based on abstract review:- 
 
- 72 not  original data 
- 292 no validated measure of PTSD or anxiety or 
depression 
45 full text reports retrieved for evaluation by both raters 
- 37 data out with 3 to 12 month follow-up 
 
8 meet criteria (1 subsequently excluded due to reporting 
problems) 
 
1.981 potentially relevant citations identified and 
screened for retrieval:- 
 
316 in MEDLINE 
 
1,243 from EMBASE  
 
264 from CINAHL 
 
158 from PsycINFO 
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3.3.2  Study characteristics 
All seven studies included recruited participants from general ICUs, although there 
was substantial heterogeneity in the clinical presentation of participants (Table 3.1). 
Three of the included studies [26, 29, 32] were particularly poor in terms of 
identifying the sample, merely stating the participants were recruited from general 
ICU. Further heterogeneity was seen where, two studies excluded patients with pre-
ICU psychiatric illness [30, 32], whilst two studies only included patients who had 
been mechanically ventilated [29, 32]. Moreover, minimum length of stay varied 
with four studies insisting on at least 24 hours [27, 28, 29, 30], one 48 hours [32], 
one 72 hours [31] and one 96 hours [26]. Four studies were conducted in the UK [31, 
32, 33, 34], one in Norway [30], one in Sweden [24], and one in France [27]. Four 
studies recruited from one site [26, 28, 30, 31]; one study recruited from three sites 
[32]; one study from six sites [29], and one from nineteen [27] sites. All of the lead 
hospitals for recruitment were university-affiliated, tertiary care centres in Western 
Europe. The RCT [32] reported that different recruitment rates at the three different 
sites were influenced by a number of factors including staff changes and resource 
constraint. Although all the studies recorded emotional distress measures at different 
time points, the studies’ aims varied considerably. For example, four studies sought 
to determine the prevalence and risk factors for emotional distress [27, 28, 30, 31]; 
one study aimed to evaluate the effectiveness of a rehabilitation programme [32]; 
another study set out to assess patients' perceptions of ICU experiences and their 
effect on emotional distress [29]; and another study sought to describe a multi-

































General ICU I: discharged between 
January & December 
2007; 
4 or more days in ICUc 






No significant difference over time for 
IES or HADS-D, however a significant 
reduction HADS-A. 20 participants had 
isolated IES score over cut-off, 6 had 
HADS-A or HADS-D above cut-off, 8 
had a clinically significant score in IES 
and HADS-A or HADS-D. 
Patients with high scores in IES and/or 
HADS-A or HADS-D at three months 
were younger than patients with low 
scores (age 46.3±17 versus 57±18 














I: COPD history;  
>24 hours in ICU 
E: inability to 
understand French; 













Significant decrease in HADS-A and 
HADS-D from discharge to 3 months. 
Anxiety symptoms at 3 month more 
common for those with anxiety 











































I: all emergency 
admissions in ICU>24 
hours; 
18 years or over 
E; lived more than 100 










IES    
(cut-off ≥20) 
 
HADS-A and HADS-D significantly 
reduced between hospital discharge and 
6 months, but no further reduction from 
6 to 12 months. IES-A and IES-I scores 
did not significantly change over time. 
No difference between those 
interviewed at time 1 only and those 
interviewed at 6 months for IES-I, IES-
A, HADS-A or HADS-D. Younger 






General ICU I: ICU stay of 24 hours 
or more; mechanically 
ventilated;  
18 years or over 
E: head injured; 
following elective 
neurosurgery 
















(0-8 low; 9-19 
medium; ≥20 
high levels of 
symptoms) 
Anxiety, depression, avoidance and 
intrusion scores did not significantly 







































I: 18-75 years;  
>24 hours in ICU 
E: language difficulties; 
major psychiatric illness 
(i.e. psychosis)a; 













No significant differences over time for 
HADS-A, HADS-D and IES.  
More surgical patients had a clinically 
significant depression score compared 
with medical and trauma patients.  
35% of patients had persistent PTSD 
symptoms during follow up, whereas 



















I: ICU length of stay ≥ 
72 hours 
E: major medical or 
surgical therapy 
following discharge; 
could not be readily 
traced;  
lived at a distance;  








(cut-off ≥10 for 









scale ≥ 18 ) 
 
Internal correlations were reported 
between HADS-A and HADS-D (p 
<.0001 at each time point), between 
IES-I and IES-A (p <.0001) and 
between all four psychological 
parameters ( p <.002 or greater).  
 
This study also reported that most cases 
of avoidance or intrusion were also 



































General ICU I: ICU patient and 
ventilated 
E: ICU patient <48 
hours; 
suffering from burn 
injury; unable to follow 





discharged for terminal 
care; unlikely to survive 
6 month follow-up 











The focus of this study was the 
evaluation of a rehabilitation 
programme. IES scores were lower in 
the group receiving the treatment at 8 
weeks. 
a Reference to pre-existing or history of psychiatric illness ; b Control group; c Protocol not followed as three patients with ICU stays shorter than 4 days were invited for 
follow-up due to perceived psychological problems in ICU; UTD= unable to determine; HADS= Hospital Anxiety and Depression Scale [15]; IES(-R)= Impact of 




3.3.3  Attrition 
The number of participants included in the studies varied from 48 to 255. 
Recruitment methods can be a potentially important source of bias and enrolling 
consecutive patients is the preferred method [19]. Five studies used this method [26, 
27, 28, 29 and 30]. Figure 3.2 summarises the percentages of those eligible for 
uptake to the study and those participating over time. Sukantarat and colleagues [31] 
had a recruitment rate of 9.8% which was particularly poor, whereas the French 
study [27] was particularly strong recruitment rate of 76%. Of those recruited to each 
study the retention rate was particularly poor for this same French study [27] whereas 
Rattray and colleagues [29] reported 100% retention rate (which is very unusual in a 
longitudinal questionnaire based study). The studies which recruited from a six and 
19 sites respectively [27, 29], no site level information was provided as to attrition 
rates which is poor. 
 
Only two studies reported the demographics of those refusing to consent [28, 30]. It 
is extremely important in observational studies that readers are provided with some 
indication of representativeness of the sample to the general population and the 
majority of studies were unable to provide this. Of the two that did report the 
demographics, they were younger [28, 30], had a longer ICU stay [28], and were 
more often transferred to local hospitals while still on mechanical ventilation than the 
patients who participated at baseline (during hospital admission) [30]. Patients 
declining follow-up also had significantly higher scores predicting ten year mortality 
[30], lower education levels [30], were more likely to be unemployed [30] and had 
more co-morbid illness than those who came for follow-up (not statistically 
significant) [26]. It is unclear from the study [26] whether they had already signed up 
to the study or if this was prior to consenting; clarification was sought from the 
corresponding author of this study, however no reply was received. Myhren et al [30] 
provided the greatest information of demographics of those eligible to participate and 
those lost to follow-up.  
 
In the largest study [30], data was reported on participants completing the 




These participants were more often mechanically ventilated, had more nursing input 
during admission, and were more often within the subset of patients admitted to 
general ICU for physical trauma compared with participants who completed at one 
month [30]. This study also looked at precipitating factors and found those lost to 
follow-up had lower educational status and were more often unemployed before ICU 
stay compared with those who completed the study at 12 months but did not differ in 
clinical characteristics [30]. 
 
 
a No information provided for eligible participants and controls group presented in graph 
 




Two studies compared psychological characteristics of those lost to follow-up with 
those completing the study [28, 30]; one found no significant differences in PTSD 
avoidance or intrusion symptom sub-scale scores at discharge or six months later 
(total PTSD symptom scores were not reported) [28]. Another study found no 
significant difference between completers and those who dropped out on PTSD total 
scores [30]. Moreover, no differences in anxiety or depression were observed 




follow-up were more anxious at baseline than those who completed. This is 
inconsistent with Rattray et al [28] findings which state no evidence of withdrawal 
bias with regards to outcome measure results. One study [30] also compared the sub-
group that completed at twelve months but not at three months (n=27) and found that 
those that did not respond at three months had significantly higher IES total mean 
score at twelve months compared with patients who answered at all three time points. 
This study [30] also found that those lost to attrition at three months did not 
significantly differ in anxiety or depression scores. Again, the Norwegian study [30] 
provided the most robust information on emotional outcomes of those eligible but 
did not participate and those lost to follow-up which is extremely important to 
identify representativeness and the potential for selection bias. 
 
3.3.4  Outcome measures 
Self-report questionnaires were used in all studies to measure levels of emotional 
distress. The Impact of Events Scale (IES) [33] or the Impact of Events-Scale 
Revised (IES-R) [34] was used to evaluate PTSD symptoms. The HADS [15] was 
used in all studies to measure symptoms of anxiety and depression. One study 
administered the questionnaire over the phone [27]; four in-person [26, 28, 31, 32], 
and two posted out questionnaires [29, 30]. Notably, not all of the studies used the 
same cut-off score for specific levels of emotional distress (see Table 3.1). 
Sukantarat et al. [31] reported intrusion and avoidance subscale scores, however not 
total scores which meant that the course of PTSD could not be identified over time.  
 
The means over time, standard deviation and absolute number of people meeting 















 Characteristics of included studies 
 
 Anxiety Depression PTSD 
Months 0 3 6 12 0 3 6 12 0 3 6 12 
Mean 
Score 








































No studies 2 3 3 3 2 2 3 3 0 3 2 2 
UN is data unavailable; * caseness refers to HADS Anxiety ≥11; HADS Depression ≥11; IES-R≥ 33; 
 
From the data available to the authors, the mean percentage of clinical caseness for 
anxiety, depression and PTSD over time was calculated as well as the respective 
linear trends from the data available and reported in Figure 3.3 with the longitudinal 
course of PTSD following rape [17] for comparison. There was no significant change 
in PTSD symptoms [26, 28, 29, 30, 31]; depression or anxiety scores [26, 29, 30, 31] 
over time in the majority of studies. Two studies did note a reduction in anxiety 
scores [27, 28]. However the tests of overall mean values hide individual difference 
profiles, so although overall there is little shift in average group scores, changes 
appear to occur at the intra-individual level. For example, the largest study reported 
the course for individuals over time, where 33% demonstrated persistent PTSD 
symptoms, 38% never met threshold for PTSD and 16% of individual’s scores 




                                                 





Fig 3.3  Mean clinical caseness (and linear trend) for post ICU anxiety, depression 
and PTSD plotted against clinical rate of change of PTSD symptoms in rape victims 
 
3.3.5  Missing data 
Two studies stated how incomplete data was managed [29, 30] - for all other studies 
it was impossible to determine how the missing data was dealt with. Given the high 
rates of attrition, particularly in the French study [27] it is unclear whether attrition 
bias was observed as missing data was not described. 
 
3.3.6  Reporting quality of studies included 
The reporting quality of the included studies is reported in Table 3.2. The intra-class 
coefficient was Cronbach’s alpha of 0.919 for the reporting quality of raters AK and 
KYM.  Areas of weakness for all studies included explaining why a study size was 
used and the potential for bias in the study results. The relative strengths of these 
papers were that specific objectives were defined, details of the eligibility criteria 
was highlighted as well as sources of participants and methods of selection of 
participants were reported.  However, it must be highlighted that although the papers 


























































































































































































* * * *  * * * * * * * * * *  * * * * * * 
De Miranda 
(2011) 
* * * *   * *   * * * * * *  * * * * * 
Rattray 
(2005) 
* * * * * * * * *  * * * * * * * *  * * * 
Mhyren 
(2010) 
* * * * * * * * *  * * * * * * * * * *  * 
Rattray 
(2010) 
* * * * * *  *   * * * * *  * * * * * * 
Schandl 
(2011) 
* *  * *  * *   * * * * * *  *    * 
Sukantarat 
(2007) 
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3.4.  Discussion 
3.4.1   Overview 
Our findings suggest that one month following discharge from hospital, ICU 
survivors commonly experience clinically significant levels of anxiety; depression, 
and PTSD symptoms and it appears likely that these rates change little over the 
subsequent eleven months. Although existing studies are heterogeneous and differ in 
important ways, the evidence indicates that about one in six survivors report 
significant levels of anxiety; about one in eight significant levels of depression and 
about one in four have clinically meaningful levels of PTSD symptoms over the first 
year of recovery. There is some evidence (from two studies) that at discharge, nearly 
one in four ICU survivors may be experiencing clinical levels of anxiety but this 
seems to have resolved for many one month later. The prevalence of anxiety and 
depression 12 months after leaving hospital is about twice that found in the general 
population (7% and 5%, respectively). The levels of PTSD co-morbidity appear to be 
considerably lower (about 40%) in ICU than is generally found to be the case (about 
80%) in the general trauma literature [12].        
 
The numbers of people with clinically significant levels of PTSD symptoms do not 
attenuate over time, which usually occurs following traumatic events. For example, 
epidemiological studies of trauma in various populations show rates of 47% and 23% 
at 3 months and 37% and 16% twelve months later for rape and road traffic accidents 
respectively [17, 353]. Unfortunately the two studies that collated PTSD scores at 
baseline only reported levels of intrusion and avoidance symptoms and not total 
scores.   
 
3.4.2 Strengths and limitations of review  
The study samples were heterogeneous in many ways which, whilst consistent with 
previous reviews in this clinical area, could impact on results. Most studies were 
conducted at university teaching hospitals and all were within Europe. However, the 
extent to which these healthcare organisations were similar and dissimilar is unclear 
and of course it is uncertain whether or not these findings can be generalised to non-
                                                 
3 From personal communication (1 July 2012) with the Journal of Critical Care, exceptions can be 




teaching hospitals and other parts of the world. The fact that across studies 
differences were evident in the average age of participants; percentages of males 
participating; overall uptake rate from potential participant pool, and clinical 
presentations included may account for a degree of the variability in results. 
Exclusion of pre-ICU psychiatric illness criterion in some studies would likely have 
led to conservative estimates of significant emotional distress, partly because 
previous mental health problems is a well recognised vulnerability factor in the 
development of PTSD symptoms following traumatic events [12]. Many studies 
reviewed did not explore potential differences between those who completed the 
study and those who were lost to attrition. Of those that did, lower education levels 
and being unemployed were notably more common among non-completers [30]. 
Again, this is important because both of these factors frequently co-occur and are 
associated with higher rates of mental health problems [14]. 
 
Clearly, the reliability and validity of outcome measures are crucial. All review 
studies used the HADS to measure anxiety and depression symptoms. This is an 
extremely well-researched measure [16] and is commonly used clinically and in 
research on adults who have physical health problems. Although the HADS is 
recommended for use in ICU settings [36], it has not been validated with ICU 
populations. There are potential confounding items - for example, a participant’s 
response to “I feel as if I am slowed down” may be due to symptoms of depression 
but similarly be influenced by medication or physical limitations of conditions. On 
the other hand, the HADS has been validated for use with many different medical 
conditions [16] and this kind of symptom overlap would commonly occur. The 
majority of papers used the IES to assess PTSD symptoms. The IES measure is 
limited in that it does not measure hyper-arousal which is a core facet of PTSD [13], 
however it is a widely used inventory and like the HADS has been extensively 
researched and deployed. Little is known about the pre-ICU psychological health of 
study participants. We do know that chronic ill-health is associated with substantially 
higher levels of anxiety and depression than occurs in the general population [37], so 
any pre-existing medical conditions could be influential in study results. Moreover, 




significant risk for post-ICU distress as well as post-ICU memories of frightening or 
psychotic experiences during patients’ time in ICU. This review did not find female 
sex, duration of mechanical ventilation, ICU length of stay or relative youth to be 
consistent predictors, whereas female sex, younger age and pre-existing 
psychological distress have been identified as key vulnerability factors for distress in 
the general trauma literature [14]. However, this review this is consistent with a 
previous review [10] looking at PTSD post-ICU which found female sex and 
younger age to be less consistent predictors but that review [10] also had many 
limitations similar to our review, such as heterogeneity of clinical presentations.  
 
Over half of the studies in this review were published in the last two years suggesting 
an increased awareness and research focus of the psychological outcomes following 
ICU admission. Our findings indicate lower prevalence rates than older systematic 
reviews within ICU [9, 10]. Our presentation of results attempts to highlight the 
general trend of clinical caseness over time in order to improve on previous reporting 
of median point prevalence rates. Median point prevalence rates do not allow 
separation of participants between those who do and do not report clinically 
significant levels of psychological problems, and this is important to clinicians and 
health care managers, alike. We have also deliberately used standard clinical cut-off 
values on the HADS of ≥ 11 to try to avoid the possibility of inflated rates of anxiety 
and depression (previous reviews used the borderline-clinical levels of ≥8).  
 
The fact that different studies used dissimilar cut-off points to indicate clinical levels 
of psychological problems is unsatisfactory (some data could not be used in results), 
but nevertheless the results of the seven studies were broadly in keeping with one 
another. The studies reviewed used the same measures which helped illuminate 
findings as it is commonly highlighted in systematic reviews of psychological topics 
that the array of different measures used causes problems when comparing results in 







3.4.3  Implications for current practice and future research 
Recent critical care guidelines [4] (derived mostly from clinical opinion due to the 
scarcity of research) recommend that psychological screening should be carried out 
during admission to ICU and at two to three months follow-up. Evidence herein 
indicates that this would likely be helpful, not only because it is important that health 
care systems consider physical and psychological wellbeing, but also because they 
are naturally entwined [37]. For example, it is well documented that when someone 
experiences clinical levels of emotional distress, they may be more likely to miss 
hospital appointments; struggle to cope with any physical impairment; find it 
difficult to adhere to rehabilitation and self-management regimens, and become less 
engaged in life in general [38]. Therefore, early identification would be prudent to 
increase chances of physical recovery; improve overall quality of life, and reduce 
health care need.  In the United Kingdom, clinical guidelines [4] recommend post-
discharge care pathways and this approach would appear sensible in view of the 
lasting psychological difficulties identified.  
 
There is a clear need for multi-centre observational studies involving large numbers 
of participants with longer follow-up periods. This is required both for ICU survivors 
as a whole and also for sub-groups.  
 
Exploration of potentially important factors before; around, and after ICU admission 
may yield clinically useful information and help health care systems target especially 
vulnerable groups and identify risk and protective factors. Importantly, it appears that 
the majority of people admitted to ICU do not suffer significant psychological 
problems. This resilience has similarly been recognised in the general trauma 
literature and has led to substantial interest in the concept of post traumatic growth 
(positive changes that occur following traumatic experiences) [39].  
 
3.4.4  Conclusions 
There appears to be elevated levels of psychological problems among ICU survivors. 
Unusually, PTSD symptoms do not seem to attenuate over time and the reason for 




a growing interest in the psychological wellbeing of ICU survivors post-discharge. 
Larger, multi-centre, higher quality studies are required and a robust, widely-
accepted methodology for assessing the quality of observational studies would be 
helpful. At our current levels of understanding, it is evident that ICU survivors 
require psychological care as well as physical rehabilitation. It is likely the two are 
intimately entwined and health providers should consider carefully the need for 
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4. BRIDGING CHAPTER  
4.1  Intensive care and psychological outcomes 
Every year a significant number of people in the United Kingdom require admission 
to intensive care for the treatment of life-threatening illness (National Institute of 
Health and Clinical Excellence (NICE), 2009). Due to the advances in critical care 
medicine within ICU settings, an increasing number are surviving a life-threatening 
illness (Angus & Cartlet, 2003). As a consequence, the focus of research has shifted 
from mortality rates to longer-term patient outcomes, both physical and 
psychological.  
 
Research in the field has demonstrated that ICU survivors report poorer quality of 
life compared to the general population (Dowdy et al., 2005; Myhren et al., 2010). 
Furthermore, as detailed in the preceding systematic review (Matheson, 
unpublished), patients surviving critical illness have been found to have persistent 
levels of emotional distress one to twelve months post ICU discharge. Although it 
can be helpful to identify specific psychological disorders such as post-traumatic 
stress disorder (PTSD) and depression in isolation, it is also important to look at 
emotional outcomes in a broader sense as, for example, it is argued that PTSD has a 
multi-factorial aetiology and multi-dimensional presentation (Brewin et al., 2000).  
 
What remains unclear is if ICU admission itself is an independent risk factor for 
psychological distress or whether other variables (including pre-existing emotional 
distress, the lasting effects of medical conditions themselves, treatments and/or 
physical recovery processes) confound post ICU psychological outcomes. While a 
history of mental health problems prior to critical illness could be the primary risk 
factor for post-ICU emotional distress, few studies have examined prior 
psychological disorders as potential risk factors (Davydow et al., 2008; 2009). There 
is limited research reporting pre-existing psychological distress for PTSD in general 
(NICE, 2005). 
 
Intensive Care Unit (ICU) admission for the treatment of critical illness is an issue of 




account for approximately one in five admissions (Scottish Intensive Care Society 
Audit Group, 2011). One of the most prevalent long term conditions in Scotland is 
diabetes with 247,278 living with a diagnosis of the condition in 2011 (Scottish 
Government, 2012). A recent national diabetes survey has highlighted that over £301 
million per year is spent providing inpatient care in Scotland for people with diabetes 
(Scottish Government, 2012). Reducing the number of diabetes emergencies (which 
are a financial burden on the NHS) is a national action point. Two major causes of 
emergency situations for people with diabetes are hypoglycaemia and diabetic 
ketoacidosis which are experienced by both people with Type 1 and Type 2 diabetes.  
 
4.2 Diabetes  
4.2.1 Type 1 diabetes 
Approximately 3,042 people are known to have Type 1 diabetes in National Health 
Service (NHS) Grampian. The prevalence rate has been steadily rising over recent 
years and in 2010 over 28, 272 people in Scotland had a diagnosis of this long term 
medical condition (Scottish Government, 2012).  
 
Type 1 diabetes arises when the pancreas is no longer able to produce insulin 
because the beta cells that do this have been destroyed by the body’s immune system. 
Insulin is the hormone that is fundamental to the process of turning glucose in the 
blood (obtained through consuming carbohydrates) into stored energy; hence when 
there is an insulin deficit this leads to an increase in glucose levels in the blood. Type 
1 diabetes is most commonly identified in children and young adults. About 11.4% 
of those with diabetes have Type 1 diabetes.  
 
4.2.2 Self-management in Type 1 diabetes 
Before the discovery of insulin in the 1920s, most people who developed Type 1 
diabetes died within 12 months. In order to survive, people with Type 1 diabetes 
need to administer daily injections of insulin. In addition to this, to prevent acute 
complications, people with Type 1 diabetes need to maintain their blood glucose 
levels within certain limits, which require continual adjustments to their insulin 




to medications and fundamental aspects of life are typically referred to using the term 
“self-care” or “self-management”. Health professionals describe the outcome of 
efforts to self-care as “diabetes control” which is frequently measured by 
haemoglobin (HbA1c). This is a form of glycaeted haemoglobin and is the standard 
measure of blood glucose control over the preceding three month period. In the short 
term if adequate control is not achieved, then blood sugar levels will become either 
too high (hyperglycaemia) or too low (hypoglycaemia) and both can lead to coma 
and death. In Scotland, most people with diabetes do not attain good control (Short 
Life Working Group on Type 1 Diabetes, 2009). Although there is no evidence on 
exactly what average blood glucose level is required to minimise the probability of 
long-term diabetes-related complications, there is an abundance of evidence showing 
that lower HbA1c values lead to better health outcomes – for example, the Scottish 
Intercollegiate Guideline Network (SIGN) 116 guidelines recommend an HbA1c of 
approximately 7% (53mmol/mol) to minimise the risk of onset and progression of 
diabetes-related eye disease. 
 
4.2.3 Emotional distress and diabetes 
Barriers for people to effectively manage their diabetes vary. Many of the difficulties 
people experience when trying to improve their diabetes control relate to how they 
think about themselves, their beliefs about their condition and to their emotional 
wellbeing in general.  Typically, these factors are related. For example, meta-
analyses have indicated that depressive and anxiety symptoms are associated with 
poorer blood glucose control (Lustman et al., 2000; de Groot et al., 2001; Anderson 
et al., 2002). However, identifying depression and anxiety in people with diabetes is 
notoriously difficult due to symptom overlap with diabetes (CMO Psychology 
Advisory Committee, 2003). For example the physiological features of depression 
(such as increased sympathetic activity) may contribute directly to hyperglycaemia 
associated with Type 1 diabetes (Musselman et al., 2003). This is of considerable 
importance because the prevalence of depression among people with diabetes is 
about 10 to 20% (Anderson et al., 2001) and that of anxiety ranges from 14 to 49% 





4.3 Diabetic ketoacidosis 
4.3.1 Diabetic ketoacidosis 
The most dangerous complication of Type 1 diabetes is diabetic ketoacidosis (DKA) 
which is characterised by hyperglycaemia, acidosis and ketonaemia.  Common 
presenting symptoms are vomiting, dehydration, hyperventilation and drowsiness. Its 
underlying causes include substantial and enduring difficulties around self 
management, and acute infection. DKA is a critical life-threatening condition and in 
the United Kingdom those with DKA are frequently admitted to ICUs in line with 
the nationally agreed protocol (NHS Diabetes, 2010).  
 
DKA is treated using a combination of frequent insulin injections, rehydration by 
intra-venous tools, replacing any minerals and in those who are unconscious. A 
feeding tube can be used to remove stomach contents in order to prevent people 
breathing in vomit.  
 
4.3.2 Complications of diabetic ketoacidosis 
A number of serious complications of DKA can occur, including acute kidney 
failure, cerebral oedema, and adult respiratory distress syndrome. Mortality in the 
United Kingdom from DKA is low at approximately 2% (Wright et al., 2009), 
however, this increases in those aged over 30 years (Skrivarhaug et al., 2006), in 
recurrent admissions, clinic non-attendance, with alcohol abuse and poor glycaemic 
control (Wright et al., 2009). In both males and females, incidence of DKA and 
mortality are also associated with psychosocial problems (Wright et al., 2009). Risk 
factors for admission with DKA include psychological problems and lower socio-
economic status (Wright et al., 2009).  However death from DKA is potentially 
avoidable as the condition is largely preventable if patient education and access to 
care are adequate (Kitabachi et al., 2009).  
 
4.3.3 Ketones 
Providing there are no complications, patients should be able to leave hospital when 
they are well enough to eat and drink normally and they have no or very small 




Ketones are acidic compounds remaining when the body burns its own fat. When the 
body has insufficient insulin, it cannot get glucose from the blood into the body’s 
cells to use as energy and will instead begin to burn fat. In Type 1 diabetes high 
blood sugar levels can produce ketones. Ketones are dangerous at high levels, and 
are those with Type 1 diabetes are at risk of ketoacidosis when blood glucose levels 
become too high.  
 
4.3.4 Clinical management of diabetic ketoacidosis 
As per the Joint British Diabetes Societies guideline for the management of DKA 
(Savage et al., 2011), the Diabetes Specialist Inpatient Team must always be 
involved in the care of those admitted with DKA. Their role is assessment of 
precipitating factors, management, discharge, provision of self-management tools 
(e.g. ketone meters) and follow-up (including assessment of the patient’s 
understanding of diabetes, their attitudes and beliefs).  
 
4.4 Summary 
It is apparent that admission to ICU is increasingly important in Scotland and in 
particular for those with long term conditions which account for one in five ICU 
hospital admissions. One of the most prevalent chronic conditions is in Scotland is 
Type 1 diabetes.  Overall, there is reasonable evidence, that there is considerable 
interplay between diabetes control and emotional wellbeing and based on the 
previous systematic review (Matheson, unpublished) there is evidence of increased 
psychological problems among those discharged from ICU with non-diabetes related 
conditions. As far as the authors’ are aware, there is no existing literature on the 
psychological outcomes among adults with diabetes following admission for DKA. 
The primary aim of this study therefore is to investigate the symptoms of PTSD; 
anxiety, and depression among adults with Type 1 diabetes who have been 





5.  METHODOLOGY  
 
Overview 
This study investigated the emotional distress of patients following admission for 
diabetic ketoacidosis (DKA).  
 
5.1 Design 
This study is a prospective longitudinal cohort study.  
 
5.2 Participants 
The sample comprised people with Type 1 diabetes who had been admitted to 
Aberdeen Royal Infirmary (ARI) for the primary reason of DKA between 1st 
September 2011 and 31st March 2012. The diagnosis of DKA was made by the 
inpatient diabetes team.  
 
5.3 Inclusion and exclusion criteria 
5.3.1 Inclusion criteria 
All participants were required to have:- 
• A diagnosis of DKA (Ketonaemia 3 mmol/l and over or significant ketonuria, 
and blood glucose over 11 mmol/l or known diabetes mellitus and HCO3 below 
15 mmol/l and/or venous pH less than 7.3) as defined by National Health Service 
(NHS) Diabetes (2010). 
• A pre-existing diagnosis of Type 1 diabetes prior to admission to tertiary care 
(that is, they were not admitted immediately following (probable) diagnosis in 
general practice or elsewhere).  
• The capacity to consent to the study (this decision was made by the consultant 
diabetologists). 
• Had their acidosis corrected and be eating and drinking (these judgements were 
made by the inpatient diabetes team). 






5.3.2 Exclusion criteria 
There were no criteria other than not meeting the inclusion criteria.   
 
5.4 Procedure 
5.4.1 Recruitment procedure 
All potential participants were approached by a senior member of the diabetes 
inpatient medical team and asked if they wished to be approached about taking part 
in this study (agreed with the NHS North of Scotland Ethics Committee; approval 
Appendix 5). If they agreed, the author was contacted and attended the ward to 
explain to the potential participant what the project entailed and answer any 
questions. An information sheet (Appendix 6) was also provided for potential 
participants to read. Potential participants who continued to express an interest in 
taking part were then presented with a consent form to sign (Appendix 7). A 
diagrammatic representation of the sequence of events leading to participants 
providing consent is presented in Figure 5.1. 
 
5.4.2  Assessment procedure 
All participants were given three questionnaires at two time points - during 
admission to ARI for DKA (baseline) and three months post-discharge (follow-up). 
The measures used are described below (section 5.5). 66% of eligible participants 
completed all inventories at baseline. 77% of those who completed the 
questionnaires at baseline also returned all inventoriesat three month follow-up 
(therefore 51% of those eligible completed the inventories at both time points). A 
diagrammatic representation of the recruitment and assessment timeline is presented 
in Figure 5.1. 
 
5.5 Measures    
As indicated previously, a total of three measures were used and these are discussed 
in following sections (5.5.3 to 5.5.5). A description of the medical and demographic 






Figure 5.1: Recruitment and assessment time line:- 
 
 
Diabetes inpatient medical team 
identified potential participants 
(i.e. meeting inclusion criteria as 
per 5.3.1) and asked potential 
participant if they wanted to take 
part in the study.  
(n=47) 
Potential participant agreed, 
author approached on ward and 
provided with verbal and written 
information and if continued to 
express an interest in taking part 
were then presented with a 




5 no pre-existing diagnosis of type 
1 diabetes; 2 lack of capacity to 
consent; 1 died and 1 could not 
speak English language; 




Three months after consent was 
signed, the same questionnaires 
are posted out to participant and a 
stamped addressed envelope (with 




If scoring at clinical significance 
for anxiety and/or depression 
and/or PTSD, letter sent to 
participant, their GP and diabetes 
team to inform them of score (see 
Appendix 9 and 10) 
 
Patients admitted to Aberdeen 
Royal Infirmary for diabetic 
ketoacidosis from 1 September 
2011- 31 March 2012 
(n=56) 
Letter sent to GP and diabetes 
team informing them that the 
patient has agreed to participate in 
study (see Appendix 8) 
 
Baseline 







5.5.1 Demographic & pre-existing clinical information  
Demographic data (sex, age) and clinical data (duration of diabetes, previous DKA; 
number of contacts with Diabetes team in year preceding DKA; precipitant to DKA; 
length of hospital stay; pre-existing levels of anxiety and depression) were obtained 
from medical records and SCI-DC Network (a national diabetes database) and 
provided information of participants’ clinical presentation and histories.  
The Scottish Index of Multiple Deprivation (SIMD) quintiles were used to describe 
the relative deprivation of those admitted for DKA, with group 1 being the most 
deprived and group 5 being the least deprived.  
5.5.2 Diabetes control 
Diabetes control (HbA1c) is the internationally recognised standard measure of 
glycaemic control and is the most often cited as the most reliable, long term indicator  
of risk of  long term complications among people with Type1 diabetes (World Health 
Organisation (WHO), 2011; Scottish Intercollegiate Guidelines Network (SIGN), 
2010). Diabetes control provides an indication of average diabetes control over 
approximately the previous three months. An indication of pre-existing glycaemic 
control was obtained by obtaining the most recent HbA1c reading (prior to hospital 
admission). The date of this reading was also recorded. Similarly, post-discharge 
HbA1c values were obtained for participants in order to ascertain glycaemic control 
following hospitalisation (only values which were collected at least three months 
post-discharge were documented as values collected before this time would be 
skewed due to the high levels of blood sugar levels during the DKA event). The 
overall mean and standard deviation of HbA1c for adults with Type 1 diabetes in 
Grampian (N= 2968; excluding the DKA study sample) was calculated using data 
obtained from SCI-DC Network (a national diabetes database used in routine clinical 
practice across primary and secondary care in Scotland). The purpose of this was to 
decipher whether this study’s sample was representative, in terms of diabetes control 






5.5.3 The Hospital Anxiety and Depression Scale  
Description of the Scale 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) was 
used as a brief screening tool for anxiety and depression. It is short (14 items) and 
controls for the overlap between somatic symptoms of medical conditions and the 
somatic symptoms of anxiety and depression. The scale is divided into two scales 
(anxiety and depression), both of which contain seven items. Respondents are 
required to consider each item in relation to the extent to which they have felt this 
way during the past week and to specify their response on a four point Likert scale. 
Each of the items is on a scale from 0 to 3 with three indicating the highest symptom 
severity and a total score for each subscale is derived by summing all the item scores 
for that sub-scale. The scores on the HADS can be separated into three categories, 
whereby a total score on each subscale defines the category. A subscale score of 0 to 
7 indicates ‘Normal’(referred to as non-case), a subscale score of 8 to 10 is defined 
as ‘Mild’(referred to as borderline-case) and a score of 11 or greater indicates 
‘Severe’ (referred to as case) (Zigmond & Snaith, 1983). The cut-off of 11 or more is  
used in this study to define clinical caseness. A copy of the HADS is presented in 
Appendix 11. 
 
Psychometric Properties of the HADS 
Each subscale of the HADS is reported to have high internal consistency, with 
correlation coefficients ranging between r=.80 and r=.93 for the anxiety subscale and 
r=.81 and r=.90 for the depression subscale (Herrmann, 1997). In a comprehensive 
review of 747 articles, Bjelland et al. (2002) demonstrated that the HADS has good 
external validity. Zigmond and Snaith (1983) reported that the HADS can reliably 
detect anxiety and depression and perform well in assessing symptom severity. The 
HADS is the most widely used self report screening tool for anxiety and depression 
in adults with medical conditions, including diabetes in the UK (Scottish 
Intercollegiate Guidelines Network, 2010). Some of the reasons for the high usage 
include: it is brief and simple to administer, it appears to separate anxiety from 
depression and it is not confounded by physical illness to the same extent as 




Although there is no good quality evidence ascertaining the validity and reliability in 
those with Type 1 diabetes, the use of the HADS with adults who have diabetes in 
Scotland was recommended by an expert panel (Psychology Working Group, 2006).  
 
5.5.4 Impact of Events Scale - Revised 
Description of the Scale 
The Impact of Events Scale-Revised (IES-R; Weiss & Marmar, 1997) is a 22-item 
self-report scale assessing subjective distress after a stressful life event. The IES-R 
outlines eight items relating to experience of traumatic intrusions (such as thoughts, 
feelings or images of the event), eight items pertaining to experiencing avoidance 
(such as trying to avoid reminders of the trauma or dulling their emotional reactions 
to it) and six items related to hyperarousal symptoms (such as feeling irritable or 
being easily startled). Participants are asked to rate the degree of distress caused by 
each item within the past seven days on a four-point scale (scoring 0 if an item is not 
distressing at all, to scoring 4 if the item has been extremely distressing). 
Participants’ ratings generate a total IES-R score (the sum of the subscale scores). A 
cut-off of 33 has been cited to provide the best diagnostic accuracy (Creamer et al., 
2003) and was applied in this study. A copy of the IES-R is presented in Appendix 
12. 
 
Psychometric Properties of the IES-R 
The IES-R is a modified version of the Impact of Events scale (IES; Horowitz et al., 
1979) which did not include the subset of hyperarousal and a question about 
flashbacks. Weiss and Marmar (1997) intended the IES-R to be comparable with the 
original scale, adding to most of the original questions. The IES specifically is 
considered a reliable tool, with high internal consistency (reflected in Cronbach’s 
alpha ranging from .87 to .91 for intrusions, .84 to .85 for avoidance and .79 to .9 for 
hyperarousal) (Sundin & Horowitz, 2002). The IES-R measure has demonstrated 
reliability within a variety of trauma-exposed populations, including burns and 
cardiac events (Sveen et al., 2010; Baumert et al., 2004). Studies examining the 
factor structure of the IES-R have found different factor solutions varying from one 




Creamer et al., 2003: Morina et al.,2010). Creamer et al. (2003) report that a total 
score of 33 on the IES-R yields diagnostic sensitivity of .91 and specificity of .82.  
 
The IES-R is recommended as a self-report measure for post traumatic stress 
disorder symptoms (National Institute of Clinical Excellence (NICE), 2005). To date, 
the IES has been used in a number of prospective studies investigating PTSD 
symptoms following admission for a medical emergency, such as severe critical 
illness, severe trauma and chronic obstructive pulmonary disease (Jones et al., 2001; 
Tøien et al., 2010; de Miranda et al., 2011). Although there is no good quality 
evidence establishing reliability and validity of the IES-R in those with acute 
complications of Type 1 diabetes,  it was highlighted by D. Weiss (personal 
communication, 14 June 2011) that the closer the medical event is to unexpected 
threat of death, the more appropriate is the IES-R.  Though many have used the 
measure in the context of receiving a diagnosis of a potentially fatal illness, the re-
living experience is different from being actually threatened with death.  In these 
circumstances the intrusion and re-experiencing is not of a possibility in the future, 
but of an actuality that has passed (D. Weiss, personal communication, 14 June 
2011).  
5.5.5  Problem Areas in Diabetes 
Description of Scale 
The Problem Areas in Diabetes (PAID; Polonsky et al., 1995) is a screening tool 
used to identify diabetes related distress.  It is a 20-item scale that describes common 
problematic situations for people with diabetes, each representing a unique area of 
diabetes-specific emotional distress (Polonsky et al., 1995; Polonsky & Welch, 
1996). The self-report questionnaire is rated on a four-point Likert scale. Each item is 
scored one to four (1 is "not a problem" to 4 a "serious problem"). The sum of the 20 
items is multiplied by 1.25 to yield a final score from 0 to 100. A higher score 
represents greater diabetes related distress. Examples of items in the PAID include, 
“not accepting your diabetes?” and “feeling that your friends and family are not 
supportive of your diabetes management efforts?” A cut-off of ≥40 in the PAID was 




present (Pouwer et a.l, 2005; Snoek et a.l, 2000). A copy of the PAID is presented in 
Appendix 13. 
 
Psychometric Properties of the PAID 
Psychometric reports to date on the PAID have shown it to have consistently high 
internal reliability (Cronbach's alpha = .95) and to have sound two month test–retest 
reliability ( r = .83) using a sample of patients. It was also demonstrated to correlate 
strongly with a wide range of theoretically related constructs such as general 
emotional distress, depression, diabetes self-care behaviours, diabetes coping, and 
health beliefs; and to be a statistically significant predictor of glycaemic control in a 
study that tracked HbA1c for a diabetes population for one year (Snoek et al., 2000; 
Welch et al., 1995; Welch et al., 2003; van der Ven et al., 2003 . Evidence of 
construct validity has been reported based on correlations with related measures, 
including diabetes coping scales (Welch et al., 1995).  
5.6 Ethical Considerations 
5.6.1 Potential Distress to Participants 
There are no known risks in completing self-report questionnaires about emotional 
distress, and they are administered routinely in a wide variety of studies including 
areas of palliative medicine and suicidal risk (Zimmerman et al., 1995). Furthermore, 
both the HADS and the IES-R are also recommended by clinical guidance agencies 
such as National Institute of Clinical Excellence (NICE, 2005) and are used 
throughout the National Health Service as part of routine screening and service 
evaluation. However, all participants were reminded that they were free to withdraw 
at any time and that the author was available to discuss any concerns. 
 
A system of care was put in place if a participant scored at clinically significant 
levels of psychological distress at follow-up (Appendix 14). The participants were 
advised at all stages of the project that they could speak with the author or other 
suitable health professional (such as their general practitioner), if they felt this would 




 5.6.2  Informed consent 
As previously described, the participants were deemed to have capacity to consent as 
per the clinical judgement of senior members of the inpatient diabetes team prior to 
the author approaching the patient. When meeting participants for the first time, it 
was highlighted that they were free to withdraw at any time and that this decision 
would in no way affect their current or future care within the health service. The 
aims and process of the study were then outlined and the participant was asked 
whether they still wished to participate. If they agreed, they were provided with a 
consent form (Appendix 7) to read and 24 hours later should they wish to participate 
were asked to and sign. 
 
5.6.3 Confidentiality 
The confidential nature of all information collected throughout the study was 
emphasised to participants on the participant information sheet (Appendix 6) and 
during discussion on the ward. A series of measures was employed to ensure the 
highest standards of confidentiality. For the purpose of identification, each 
participant was assigned a unique number. All demographic data was then 
anonymised.  This anonymised data was transferred onto a password-protected NHS 
computer. Returned questionnaires were stored safely in a locked filing cabinet. Each 
participant’s unique identification number was the only link to their personal 
information. Personally identifiable data (e.g. name, date of birth, address) was 
stored in a locked filing cabinet on NHS premises. Only the researcher and her 
supervisors had access to this data. The author analysed the data using statistical 
software package developed for the social sciences (SPSS, Version 19). Data 
analysis took place in the author’s office, using an NHS computer, on NHS premises. 
This SPSS database was kept on a password-protected computer at all times.  
 5.6.4  Ethical approval 
An application for ethical approval was submitted to NHS Grampian North of 
Scotland Research Ethics Committee on 6 June 2011. Written confirmation of full 
ethical approval was received on 3 August 2011 (Appendix 5). Following this, the 




on 30 August 2011 gave their approval for the study to commence (Appendix 15).  
Indemnity cover was provided by the University of Edinburgh prior to the research 
commencing and by the NHS indemnity scheme. 
5.6.5 Sample size 
Sample size estimation depends on the anticipated strength of the relationships that 
are being explored (effect size) and the amount of statistical power required to be 
able to detect such effects (Field, 2005).  
 
An estimated effect size for this study was calculated based on an effect size 
obtained by a well-designed study looking at PTSD symptoms at 3 month follow-up 
with a trauma-exposed group (Conlon et al., 1998). The Cohen’s d effect size 
obtained from this study was .87 (a large effect size). Although effect sizes in 
behavioural research are generally of medium size (Cohen, 1988), in the general 
trauma literature an acute stress reaction is commonly seen after a traumatic event 
and this typically attenuates over time (National Institute of Clinical Excellence 
(NICE), 2005). Therefore, it was deemed appropriate to base the calculation 
detecting a large effect size  (d= .87) with statistical Power of .08 using parametric 
statistics 10 participants were required and non-parametric statistics, approximately 
17 participants were required (Faul et al., 2009).  
5.7 Analytic plan 
5.7.1 Hypotheses 
It was hypothesised that 
(1)  there would be a significant reduction in the number of participants reporting 
significant levels of emotional distress (PTSD; depression; anxiety; and 
diabetes related distress) between baseline and follow-up;  
(2) there would be a significant reduction in the median scores of emotional 
distress (PTSD; depression; anxiety and diabetes related distress) over 
time;(3)   those admitted for DKA would have significantly higher levels 
of anxiety and/or depression (both median scores and level meeting caseness) 




(4)  those admitted for DKA would have significantly higher levels of pre-
existing HbA1c than the overall local type 1 diabetes clinical  population. 
 
Checks of representativeness of sample 
(i) those who participated at baseline would not differ in terms of demographic 
or clinical variables compared with those who did not participate in the study 
(ii)  those who completed the study would not differ in terms of demographic or 
clinical variables when  compared with those who dropped out after baseline 
 
5.7.2  Data screening 
Exploratory data analysis was carried out to determine whether the assumptions for 
appropriate use of parametric statistics were met (Gravetter & Wallnau, 1996). To 
check whether the data was normally distributed, a frequency distribution was used 
to plot the data and check for the presence of outliers. Together with visual 
inspection of distributions, significant values (p <0.05) in the Kolmogorov-Smirov 
test were taken to indicate that the distribution was significantly different to the 
norm. As the data did not appear to meet assumptions for parametric statistics, non-
parametric statistics were employed.  
 
Non-parametric tests make fewer assumptions about the nature of the data population 
and can be appropriate for small data sets where assumptions of normality may not 
be met and where tests of normality lack power.   
5.7.3 Analysis 
Main statistics 
The Wilcoxon matched pairs test was used to evaluate potential differences between 
pre-existing and baseline; pre-existing and follow-up, and baseline and follow-up 
HADS scores and between baseline and follow-up scores on the IES-R and PAID.  
McNemar’s test was used to analyse potential differences over time in the proportion 
of participants falling in to case/ non-case categories for anxiety, depression and 





The Wilcoxon matched pairs test was also used to assess any significant difference 
between the pre-existing and follow-up HbA1c values among those who completed 
the study. Only those who completed questionnaires at both time points were 
included in the analysis.  
 
Comparison of study and non-study DKA admissions 
Chi-square test was used to evaluate potential differences between males and females 
and in levels of deprivation. Fisher’s exact test was used to explore any possible 
significant differences between pre-existing caseness for anxiety and depression. The 
Mann-Whitney U test was used to evaluate a range of potential differences between 
those admitted with DKA during the study period. This included exploring possible 
significant differences in: age; anxiety score; depression score; pre-admission HbA1c; 
number of diabetes clinic appointments attended in the year preceding admission; 
length of stay in hospital, and duration since diabetes diagnosis.  
Comparison of those who completed the study and those who dropped-out 
The above tests were run for those who completed and those who dropped out. 
Mann-Whitney U test also was used to analyse the PAID and IES-R scores between 
those who completed and those who dropped out. In addition, Fisher’s exact test was 
also used to explore any possible significant differences in caseness for PTSD 
between these two groups.  
Comparison with local Type 1 diabetes clinical population 
Chi-square test was used to evaluate differences in levels of deprivation for the DKA 
sample with the overall local type 1 clinic population.  
The Fisher’s exact test was used to explore potential differences between the study 
sample and the local type 1 diabetes clinical population in the prevalence of clinical 
levels of anxiety and depression. Mann-Whitney U Test was used to evaluate any 
differences in the continuous sample from the local type 1 diabetes clinical 




The Mann-Whitney U Test was used to identify any differences in HbA1c between 
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OBJECTIVE – The primary objective was to longitudinally investigate the levels of 
emotional distress among adults with type 1 diabetes during and post-discharge from 
hospital following successful treatment of diabetic ketoacidosis (DKA).  
 
RESEARCH DESIGN AND METHODS - Questionnaires measuring anxiety, 
depression, post-traumatic stress disorder (PTSD) symptoms and diabetes related 
distress were completed at baseline (time of hospital discharge) and at 3 month 
follow-up. Statistical analyses were conducted to examine levels of emotional 
distress over time and its relationship to diabetes control. Additional demographic 
and clinical data was also collated and analysed.  
 
RESULTS - 31 participants were recruited at baseline and 24 (77.4%) completed 
questionnaires at 3 month follow-up. Many participants reported clinical levels of 
anxiety (37.5%); depression (25%), and PTSD symptoms (37.5%) atbaseline. At 
follow-up, the prevalence of clinical levels of anxiety remained high (37.5%), 
although the rates of clinical depression (8.3%) and PTSD symptoms (8.3%) 
attenuated markedly. There was no significant change in diabetes-related distress 
scores across time (P = 0.055). Pre-existing diabetes control was considerably poorer 
in the study sample than the overall local type 1 clinical population (10.9% versus 
8.9%; P < 0.0001) and this did not improve following discharge (P =0.487). 
 
CONCLUSIONS - DKA is associated with a complex and clinically significant 
psychological reaction. In part, this is resolved in the months subsequent to discharge 
from hospital; however, clinical levels of anxiety remain commonplace. It is 
probable that these psychological problems during and after admission go undetected 
and therefore are not used routinely to inform management and intervention 
approaches.   Further investigation is warranted to identify the longer-term course of 
emotional distress following DKA to inform any associated care pathway and raise 
awareness of psychological vulnerability of this sub-group of people with type 1 





Type 1 diabetes is associated with an increased prevalence of emotional distress 
when compared with the general population. Although there is some debate about 
exact figures, the reported prevalence rate of clinical anxiety is between 14% and 
49% (approximately two to six times the general population) and of clinical 
depression is between 10% and 20% (about two to four times that of the adult 
population without diabetes) (1,2). Meta analytical studies have indicated that 
clinical anxiety and depression are associated with poorer diabetes control (HbA1c) 
(3, 4) and therefore potentially affect both shorter- and longer-term health outcomes. 
There is evidence that depression is associated with poorer lifestyle choices (e.g. 
higher rates of smoking; more sedentary life-style; and less healthy diet) as well as a 
greater risk of macro-vascular and micro-vascular complications (5,6,7,8). 
Importantly, there is some evidence that successful treatment of depression can lead 
to not only better emotional wellbeing but also lower blood glucose levels (9, 10).  
Diabetic ketoacidosis (DKA) is the most dangerous acute complication of type 1 
diabetes (11), characterised by a triad of symptoms (hyperglycaemia, ketosis and 
acidosis), which can lead to coma and death. A common precipitant to DKA is poor 
control and compliance (12) highlighting substantial and enduring difficulties around 
self management.  The underlying reasons for peoples’ difficulties in effectively 
managing their condition vary. It is clear that many of the significant barriers to 
improved diabetes control relate to beliefs that people with diabetes have about 
themselves, their condition and also relate to emotional wellbeing. Typically, these 
factors are enmeshed.  
It is commonplace that those admitted with DKA receive treatment in an Intensive 
Care Unit (ICU) (13). There has been an increasing interest in psychological 
outcomes of ICU survivors, and systematic reviews indicate a high prevalence of 
clinical levels of anxiety, depression and post-traumatic stress disorder (PTSD) 
symptoms in the months and years following hospital discharge (14, 15, 16). What 
remains unclear is whether ICU admission is an independent risk factor for 




by other factors such as sex, age or the lasting effects of medical conditions 
themselves, treatments and physical recovery processes.  
Overall, there is reasonable evidence that there is considerable interplay between 
diabetes control and emotional wellbeing, and strong evidence of increased 
psychological problems among some of those discharged from ICU with non-
diabetes related conditions. As far as the authors’ are aware, there is no existing 
literature on the psychological outcomes among adults with diabetes following 
admission to ICU for DKA. The primary aim of this study therefore is to investigate 
the symptoms of anxiety; depression, PTSD and diabetes related distress among 
adults with type 1 diabetes discharged post DKA.   
 
6.2  RESEARCH DESIGN AND METHODS  
6.2.1 Design and methods 
This is a prospective cohort study. The participants were enrolled from September 
2011 to March 2012 within an ICU unit in an adult tertiary care university-affiliated 
hospital in the United Kingdom (Aberdeen Royal Infirmary, Scotland) and follow-up 
ended in July 2012.  All patients presenting at admission with DKA (Ketonaemia 3 
mmol/l and over or significant ketonuria, and blood glucose over 11 mmol/l or 
known diabetes mellitus and HCO3 below 15 mmol/l and/or venous pH less than 7.3) 
as defined by National Health Service (NHS) Diabetes (17) were considered. Those 
with a pre-existing diagnosis of type 1 diabetes; fluent in English; the capacity to 
consent; with their acidosis corrected, and who were eating and drinking were 
eligible for inclusion in the study. All potential participants were approached prior to 
hospital discharge and informed, written consent was sought.  
Demographic data (sex, age) and clinical data (duration of diabetes, previous DKA; 
number of contacts with the Diabetes team in year preceding DKA; precipitant to 
DKA; length of hospital stay; pre-existing levels of anxiety and depression) were 




The Scottish Index of Multiple Deprivation (SIMD) quintiles were used to describe 
the relative deprivation of those admitted for DKA, with group 1 being the most 
deprived and group 5 being the least deprived.  
Participants completed the Hospital Anxiety and Depression Scale (HADS; 18), 
Impact of Events Scale-Revised (IES-R; 19) and Problem Areas In Diabetes (PAID; 
20) at baseline(prior to hospital discharge) and follow-up (3 months later) 
(questionnaires were posted to participants). The HADS is a self-report screening 
questionnaire for anxiety and depression and a score of ≥11 on either the anxiety or 
depression sub-scale indicates clinically significant levels (or “caseness”). The IES-R 
is a 22-item self-report scale and a score of ≥ 33 is commonly assumed to indicate 
clinically significant levels of PTSD symptoms (21). The 20-item PAID was used to 
measure diabetes-related distress and higher scores represent greater distress 
(maximum score 100) and a cut-off of ≥40 to indicate severe levels of diabetes 
distress.  
If there was one uncompleted item on each subscale of IES-R; HADS, or PAID then 
the missing item was allocated the mean of that sub-scale’s items, for that 
participant. This method was used for 1 participant questionnaire at baseline and 9 
participant questionnaires at follow-up. 
The HbA1c value before admission (mean = 120 days; SD = 78.5) was collected to 
assess diabetes control prior to DKA. Similarly, to ascertain post-DKA control, the 
first HbA1c value measured at least three months following discharge was obtained 
(mean=107 days; SD = 22.0). 
6.2.2 Comparative data 
The HbA1c for all adults (excluding study participants) with type 1 diabetes in the 
Grampian region (N=2968) was obtained (referred to as the overall local type 1 
diabetes clinical population herein) from SCI-DC Network and used to compare with 
the DKA sample.   
Adults with type 1 diabetes who attend the Diabetes Centre in Aberdeen are screened 




(excluding study participants) of HADS inventories collected over a three month 
period (n=390; 13% of overall type 1 diabetes clinic; referred to as the local type 1 
diabetes clinical population herein) was collected and compared with the DKA study 
sample.    
6.2.3 Power 
To detect a medium effect size with the statistical power of 0.8 at alpha level of 0.05 
using non-parametric statistics, approximately 17 participants were required (22).                               
 
6.2.4 Ethics 
The NHS North of Scotland Regional Ethics Committee approved the study. 
6.2.5 Statistical methods 
The reporting of this study conforms to the STROBE (23) statement.  All analyses 
were performed using SPSS (24).  
Main statistics 
The Wilcoxon matched pairs test was used to evaluate potential differences between 
pre-existing and baseline; pre-existing and follow-up, and baseline and follow-up 
HADS scores and between baseline and follow-up scores on the IES-R and PAID.  
McNemar’s test was used to analyse potential differences over time in the proportion 
of participants falling in to case/ non-case categories for anxiety, depression and 
PTSD symptoms. The Wilcoxon matched pairs test was also used to assess any 
significant difference between the pre-existing and follow-up HbA1c values among 
those who completed the study. Only those who completed questionnaires at both 
time points were included in the analysis.  
 
Comparison of study and non-study DKA admissions 
Chi-square test was used to evaluate potential differences between males and females 
and in levels of deprivation. Fisher’s exact test was used to explore any possible 
significant differences between pre-existing caseness for anxiety and depression. The 




those admitted with DKA during the study period. This included exploring possible 
significant differences in: age; anxiety score; depression score; pre-existing HbA1c; 
number of diabetes clinic appointments attended in the year preceding admission; 
length of stay in hospital, and duration since diabetes diagnosis.  
Comparison of those who completed the study and those who dropped-out 
The above tests were run for those who completed and those who dropped out. 
Mann-Whitney U test also was used to analyse the PAID and IES-R scores between 
those who completed and those who dropped out. In addition, Fisher’s exact test was 
also used to explore any possible significant differences in caseness for PTSD 
between these two groups.  
Comparison with local type 1 diabetes clinical population 
Chi-square test was used to evaluate differences in levels of deprivation for the DKA 
sample with the overall local type 1 clinic population. The Fisher’s exact test was 
used to explore potential differences between the study sample and the local type 1 
diabetes clinical population in the prevalence of clinical levels of anxiety and 
depression. Mann-Whitney U Test was used to evaluate any differences in the 
continuous sample from the local type 1 diabetes clinical population and study 
sample scores for anxiety and depression. The Mann-Whitney U Test was used to 
identify any differences in HbA1c between the study sample and overall local type 1 
diabetes clinical population.  
 
6.3 RESULTS 
6.3.1 Participant characteristics 
Figure 6.1 describes the recruitment and eligibility requirement for the study sample. 
Participant characteristics are detailed in Table 6.1 No significant difference 
observed between the study sample and the overall type 1 diabetes clinical 
population for deprivation (P6 = 0.841).  






6.3.2 Comparison of study and non-study DKA admissions 
Forty-seven patients were eligible to participate and 31 were recruited at baseline 
(see Figure 6.1). Although a greater percentage of those who chose to not participate 
were male (60%), the difference between male and female participation rates was not 
significant (P = 0.174).   Similarly, there was no significant difference between the 
ages of those who chose to participate and those who did not (median = 26 
(interquartile range (IQR) = 22.0) vs. 27 (IQR = 23.0) years; P = 0.598); their pre-
existing HbA1c (median = 11.4% (IQR = 4.0) vs.  12.1% (IQR = 5.1); P = 0.639); 
SIMD quintile distribution (P = 1.000); length of hospital stay (median = 2 (IQR = 
2.0) vs.  3 days (IQR = 1.0); P = 0.076); pre-existing HADS anxiety score (median = 
7.0 (IQR = 8.0) vs.  9.5 (IQR = 6.8); P = 0.268); pre-existing HADS anxiety caseness 
(P = 0.295); pre-existing HADS depression score (median = 3.0 (IQR = 7.0) vs.  8 
(IQR = 3.8); P = 0.184); and, pre-existing HADS depression caseness (P = 0.553).    
Significant differences between those who participated in the study and those who 
did not were observed in the number of attended diabetes clinical appointments in the 
year preceding DKA (median = 2 (IQR = 2) vs.  0 (IQR = 1) days; P = 0.002) and in 













Patients admitted for DKA to 




-5 no pre-existing diagnosis of 
type 1 diabetes; 
-2 lack of capacity to consent; 
-1 died; 
-1 could not speak English 
Eligible to participate in study 
and approached by principal 
investigator 
(N=47) 
Recruited at baseline 
(N=31) 
Completed 3 month follow-up 
(N= 24) 
Refused to participate 
(N= 16) 
 
Loss to follow-up (N=7) 
2 moved out of area; 




Table 6.1 – Patient characteristics 
Parameter Baseline Follow-up 
 





Female gender, %, n 61.3%, 19 66.7%, 16 
≤ 21 years of age, %, n 35.5%, 11 41.7%, 10 
Diagnosis in preceding year, %, n 16.1% , 5 12.5%, 3 
Previous admission for DKA, %, n  58.1% , 18 62.5%, 15 
   
Precipitant to DKA as noted by Diabetes Team, %, n 
• Infection 
• Alcohol misuse 
• Gastrointestinal problems 
• Missed insulin 















SIMD Quintile, % 




• 5 (least deprived) 
 
3.2%, 1  
19.4%, 6  
19.4%, 6  
29.0%, 9  








6.3.3 Comparison of those recruited who completed the study and those who 
dropped out 
A total of 31 eligible patients completed baseline questionnaires and of these 24 
(77.4%) completed the questionnaires at 3 months. There were no significant 
differences between participants completing the study and those who dropped out 
with respect to sex (57.1% of those lost to follow up were males; P = 0.255); 
deprivation (P = 1.000); age (median = 25.5 (IQR = 26.3) vs.  28 (IQR = 20.0) years;  
P = 0.636); length of hospital stay (median = 3 (IQR = 2) vs.  3 (IQR = 1) days; P = 
0.142); duration of diabetes (median = 9 (IQR = 9.8) vs.  4 (IQR = 10) years;P = 
0.102); pre-existing HbA1c (median = 10.9% (IQR = 5.5%) vs.  12.0% (IQR = 5.1%); 
P = 0.069); baseline HADS anxiety score (median = 7 (IQR = 7.5) vs.  12 (IQR = 8); 
P = 0.245); baseline anxiety caseness (P = 0.413); baseline HADS depression score 
(median = 5 (IQR = 9) vs.  10 (IQR = 6); P = 0.052); baseline depression caseness (P 
= 0.384); baseline IES-R score (median = 18.5 (IQR = 26.5) vs.  25.0 (IQR = 23.0); 




the study had significantly lower levels of diabetes related distress than those who 
dropped out (median = 40.6 (IQR = 27.2) vs.  66.3 (IQR = 16.3); P = 0.026).  
6.3.4 Emotional distress  
Figure 6.2 shows the percentage of study participants at baseline and follow-up 
scoring at clinically significant levels for anxiety (37.5% vs. 37.5%), depression 
(25% vs. 8.3%) and PTSD (37.5% vs. 8.3%) symptoms.  
The percentage of the local type 1 diabetes clinical population meeting clinical levels 
for anxiety and depression were 11.9% and 6.0%, respectively.  Pre-existing levels of 
anxiety (16.7%) and depression (16.7%) were available for 19 of the study 




Overall, there was no significant difference between pre-existing and baseline 
anxiety scores (P = 0.264) and proportion meeting caseness (P = 0.500). No 
significant difference was found between the pre-existing and follow-up anxiety 
scores (median at follow-up = 8 (IQR = 9.5); P = 0.735) or between anxiety scores at 
baseline and follow-up (P = 0.294). Similarly, there was no significant difference 
between the proportion of participants experiencing clinical levels of anxiety at 
baseline and follow-up (for both groups 37.5%; P = 1.000). Eighty-nine percent of 
those who initially had clinical levels of anxiety continued to be clinically anxious 
three months later (which was about one in three of DKA admissions overall).  
DKA sample compared with clinic 
Those admitted for DKA had significantly higher levels of anxiety at baseline (P = 
0.001) and follow-up than the local type 1 diabetes clinical population (clinical 
median = 5 (IQR = 5); P = 0.015). There was no significant difference in the anxiety 
scores of the local type 1 diabetes clinical population and pre-existing levels of 




caseness at baseline and follow-up than the local type 1 diabetes clinical population 
(clinic proportion = 11.8%; P = 0.0018). 
 
 
Figure 6.2 – The percentage of study participants meeting caseness for anxiety (■) 
and depression (□) pre-existing(n=19), baseline (n=24) and follow-up (n=24); the 
percentage meeting caseness for PTSD symptoms (   ) at baseline (n=24) and follow-
up (n=24); the percentage meeting cut-off for severe diabetes distress ( , ) and the 
percentage of local type 1 diabetes clinical population (n=390) meeting caseness for 




No significant differences were observed between pre-existing and baseline 
depression scores (baseline median = 5 (IQR = 9.5); P = 0.896) or pre-existing and 
follow-up depression scores (median at follow-up = 5 (IQR = 7); P  = 0.250). There 




0.205), nor was there any significant change in the proportion of participants 
experiencing clinical levels of depression (25% vs.  8.3%; P = 0.125). Of those 
initially reporting clinically significant levels of depression, 33.3% continued to do 
so 3 months later.  
DKA sample compared with clinic 
There was no difference between the DKA sample baseline depression scores and the 
local type 1 diabetes clinical population (median = 2; P = 0.010) or in the pre-
existing depression scores (16.7%) and the depression scores of the local clinical 
type 1 diabetes clinical population (P = 0.654). However, compared to the local type 
1 diabetes clinical population, a significantly higher proportion of participants 
crossed the threshold for caseness at baseline (P = 0.0003) but not at follow-up (P = 
0.6721). 
6.3.7 PTSD 
There was a significant reduction in PTSD symptom scores between baseline and 
follow-up (median = 18.5 (IQR = 26.5) vs.  12 (IQR = 20.0); P = 0.006) and in the 
proportion of participants experiencing clinical levels of PTSD symptoms at baseline 
and follow-up (37% vs.  8%; P = 0.016). The majority (seven out of nine; 78%) of 
those initially exhibiting clinical levels of PTSD symptoms did not do so at follow-
up.  
6.3.8 Diabetes related distress 
No significant difference was found between baseline and follow-up PAID scores 
(median = 40.63 (IQR = 27.19) vs. 38.75 (IQR = 21.88); P = 0.055).  Thirty-one 
percent met severe levels for diabetes related distress at baseline and 28% at follow-
up. 
6.3.9 Co-morbidity 
Figure 6.3 illustrates the percentage of participants who scored at clinically 




combinations of the three conditions. In all instances, where there were clinical 
levels of depression or PTSD, clinical anxiety was similarly present.    
 
Figure 6.3 – Co-morbidity of clinical levels emotional distress at 3 month follow up 




There was no significant change in diabetes control from pre-existing to follow-up (n 
= 15; follow-up median 10.6% (IQR = 6.1%); P =  0.487).   
DKA sample compared with clinic 
The study sample had significantly higher pre-existing HbA1c values than the overall 
local type 1 diabetes clinical population (median = 10.9% (IQR = 5.5%) vs.  8.9% 









6.4.1 Main outcomes 
This is, to the authors’ knowledge, the first follow up study of emotional distress 
following hospital admission for DKA, and the results indicate that there was 
substantial psychological morbidity. Almost four in ten participants reported clinical 
levels of anxiety three months after discharge, which is three times higher than the 
overall type 1 diabetes clinical population. Although the rate of caseness for 
depression was initially substantial (one in four) this fell markedly consistent with 
the local adult type 1 diabetes clinical population (about one in twelve). A similar 
pattern occurred among those who initially reported clinical levels of PTSD 
symptoms, with approximately seven in nine no longer reporting caseness at follow-
up. Overall, the results indicate that DKA admission is associated with an acute post-
traumatic stress and depressive reaction which dissipates, and an anxiety reaction 
that appears to be longer-lasting.         
6.4.2 Anxiety 
It is striking that anxiety rather than depression appears to be the dominant feature of 
those admitted for DKA. Although there is some evidence that anxiety does 
influence HbA1c values (4) there has been more interest on the role of depression in 
diabetes self-management (e.g. 3,5). There are sound theoretical reasons why anxiety 
is associated with poorer control. For instance, when the body deals with stress the 
neurendocrine system is activated and of particular importance is the hypo-pituitary-
adrenal axis (HPA) (25). Both diabetes and anxiety may be associated with an 
increased, prolonged and hyper-activation of the HPA (resulting in release of glucose 
in to the bloodstream), which makes it more difficult to control blood glucose levels 
(25). To complicate matters further, there is considerable overlap between symptoms 
of anxiety and symptoms of hypoglycaemia (e.g. increased irritability and 
physiological symptoms such as hot flushes and shaking) (26). Thus symptoms of 
anxiety can be misinterpreted as indicating low blood glucose and thereby lead to 
inappropriate self-care interventions, which in turn can raise blood glucose levels 




focus of attention on potential complications and their implications, exacerbating 
(and maintaining) high levels of anxiety. These types of worries (characteristic of 
anxiety) are compounded by the fact that routine HbA1c values are relatively high. 
That is, in part at least these fears are realistic and evidence-based (whereas most 
worries associated with anxiety disorders are imaginary and unlikely to occur).             
6.4.3 Depression   
Clinical levels of depression at three month follow up are consistent with the local 
type 1 diabetes clinical population (6.7%) and prevalence is frequently cited between 
10- 20% in the literature (2). Although not statistically significant, there is a 
substantial reduction in the number of participants reporting caseness for depression 
at  follow-up (from 25% to 8.3%). This is all the more salient because the follow-up 
figure is lower than the pre-existing rate (16.7%). It is unclear what accounts for this 
reduction in clinical depression, although it could be the case that an acute lowering 
of mood is a natural response to what is often a very frightening, uncomfortable and 
unpleasant experience.   
6.4.4 Diabetes Control 
Perhaps unsurprisingly, those admitted for DKA had poorer diabetes control than the 
local type 1 population, indicating on-going difficulties with self-management. These 
findings are consistent with previous studies of DKA samples (e.g. 27).  
6.4.5 Findings in wider context 
Our study found clinical levels of anxiety in 37.5% of participants at follow-up, 
while 8.3% met cut-off for PTSD and depression. Studies tracking emotional distress 
three months following ICU discharge report lower levels of clinical anxiety (24% to 
28%); higher levels of clinical depression (20% to24%) and considerably higher 
levels of clinically significant PTSD symptoms (45% to 52%) (28, 29). Notably, 
these studies used lower thresholds to indicate clinical levels of anxiety; depression, 
and PTSD symptoms (e.g. HADS anxiety ≥ 8) than the current study which used 
conservative thresholds (HADS anxiety or depression ≥11, and IES-R ≥33). The 




reported following the diagnosis of a chronic health condition. For example, among a 
group of adults diagnosed with prostate cancer, consistently high levels of anxiety 
were observed over time (30) and among a sample newly diagnosed with multiple 
sclerosis, depression levels were initially high however ameliorated over subsequent 
months (31).   
6.4.6 Limitations 
There are a number of limitations to this study. We have reported on a relatively 
small cohort from one centre. There was some evidence that the study sample was 
dissimilar to overall DKA admissions, for example, they attended routine diabetes 
clinic appointments more regularly. However, we found no significant difference on 
many variables investigated, and our recruitment and retention rates (66% and 77%, 
respectively) compare favourably to other studies of this type (28).      
The dataset for pre-existing levels of emotional distress was incomplete (which 
indicates they either did not attend appointments over the preceding year or declined 
to complete the questionnaire, the latter of which is very uncommon). This group 
without recorded HADS may represent an unusually vulnerable group who has 
disengaged with local diabetes services. Moreover, follow-up diabetes control data 
was also incomplete probably for similar reasons. 
6.4.7 Clinical implications and future research 
Our results demonstrate that this group is particularly vulnerable. A greater 
awareness of the psychological issues affecting people with type 1 diabetes who 
experience DKA is required. Moreover, a better understanding of the ways in which 
emotional distress can impact on one’s self management is needed as well as further 
investigation on how best to communicate this information in light of possible 
information processing deficits which may be a result of emotional distress.  
Larger, multi-site, longer term follow-up studies, perhaps across multiple countries 
with different health care systems, are required to gain a greater understanding of the 




research on the role of anxiety in efforts of people with type 1 diabetes to manage 
their condition.  
Although our data suggests that depression and PTSD symptoms largely self-resolve, 
further studies, similar to this study, should be carried out to gain a greater insight 
into the trend of emotional distress post DKA. To date it is unclear whether or not the 
trend over time of emotional distress is similar to that among the general population, 
or perhaps has a more chronic course.  
Historically, the clinical management of DKA has focused on medical issues. 
However, there is clearly a considerable psychological component that can influence 
decisions about current and future care following successful treatment of DKA. For 
example, people experiencing PTSD symptoms typically do their best to avoid re-
experiencing the traumatic event which includes being disinclined to talk or think 
about it (this could be why we found lower than expected levels of depression). 
Moreover, people exhibiting symptoms of depression are commonly lacking in 
energy and motivation, have a tendency to ruminate and feel hopeless. It is therefore 
easy to understand why it may be problematic to engage this sub-group. Difficulties 
include gathering information about their self-care regimens and decision-making; 
providing information that is relevant and facilitating helpful changes in health-
related behaviour. 
A systematic approach to identifying and helping those admitted for DKA who have 
clinically significant psychological problems that are enduring (this study indicates 
that anxiety might be the main emotional problem) would likely be beneficial to 
people with diabetes; their families, and health care providers. Especially in light of 
the marked rise of adult DKA admissions to NHS Scotland from 2003 (one year; n = 
927) to 2009/10 (one year; n > 2000) (32, 33). These findings are not isolated to 
Scotland as they are consistent with epidemiological studies in the USA. (34). 
Moreover, there may be scope for multi-disciplinary interventions targeting this 
group who appear vulnerable to emotional distress; chronic poor control, and 






Overall, the results of this study suggest an acute PTSD-like and depressive reaction 
following DKA is common but subsides, whereas clinical levels of anxiety seems to 
persist over time. Further investigation of the course of emotional distress post DKA 
is warranted, including looking at psychological outcomes in a larger sample and 
over a longer period. This preliminary research suggests that those admitted for DKA 
require psychological as well as medical support. Innovative, multi-professional care 
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NIH Public Access Policy Compliance 
To comply with the NIH Public Access Policy, Elsevier will deposit to PubMed 
Central (PMC) author manuscripts on behalf of authors reporting NIH funded 
research. The NIH policy requires that NIH-funded authors submit to PubMed 
Central (PMC), or have submitted on their behalf, their peer-reviewed author 
manuscripts, to appear on PMC no later than 12 months after final publication. 
Elsevier will send to PMC the final peer-reviewed manuscript, which was accepted 
for publication and sent to Elsevier's production department, and that reflects any 
author-agreed changes made in response to peer-review comments. Elsevier will 
authorize the author manuscript's public access posting 12 months after final 
publication. Following the deposit by Elsevier, authors will receive further 
communications from the NIH with respect to the submission. 
 
Note: Authors must declare their NIH funding (or the other funding bodies listed 
below) when completing the copyright transfer form. 
 
Other Funding Body Policies  
Elsevier has also worked with the following funding bodies to ensure that our authors 




- Arthritis Research Campaign (UK) 
- British Heart Foundation (UK)  
- Cancer Research (UK)  
- Chief Scientist Office  
- Department of Health (UK)  
- Howard Hughes Medical Institute (US)  
- Medical Research Council (UK)  
- Wellcome Trust (UK) 






Contributors are provided with proofs and are asked to proofread them for 
typesetting errors. Important changes in data are allowed, but authors will be charged 




Reprints of articles can be furnished to contributors when ordered in advance of 
publication. An order form, showing cost of reprints, is sent with proofs. Individuals 
wishing to obtain reprints of an article that appeared in the Journal of Critical Care 




Announcements of meetings, conferences, and the like that are of interest to the 
readership of the Journal of Critical Care should be sent to the Editor at least three 
months before the first day of the month of issue.  
 






































































Diabetes Care Instructions for Authors 
Last updated on February 29, 2012. 
Please read the complete instructions for authors before submitting your manuscript 
to Diabetes Care via http://mc.manuscriptcentral.com/diabetescare.  
 
1. ABOUT THE JOURNAL 
Diabetes Care is a journal for the health care practitioner that is intended to increase 
knowledge, stimulate research, and promote better management of people with 
diabetes. To achieve these goals, the journal publishes Original Articles on human 
studies in the following five categories:  
1) Clinical Care/Education/Nutrition/Psychosocial Research 
2) Epidemiology/Health Services 
3) Pathophysiology/Complications  
4) Cardiovascular and Metabolic Risk  
The journal also publishes clinically relevant Review Articles, Letters to the Editor, 
Brief Reports, and health/medical news or points of view. Topics covered are of 
interest to clinically oriented physicians, researchers, epidemiologists, psychologists, 
diabetes educators, and other health professionals. The journal does not publish 
descriptions of study designs without data, papers on in vitro studies, or studies 
involving animals.  
The editor-in-chief of Diabetes Care, William Cefalu, MD, began his term with the 
January 2012 issue. Dr. Cefalu's editorial team began reviewing first submissions on 
July 1, 2011.  
Editorial Note: Due to an increasing number of submissions and limited editorial 
space, manuscripts will initially be reviewed by an editorial committee and/or the 
editor. Manuscripts that exceed the word limit will be automatically declined, and 
only those that meet a priority score above the 50th percentile will be reviewed. 
 
2. POLICIES 
ADA's Publications Policy Committee follows the recommendations of the 
International Committee of Medical Journal Editors (ICMJE), the World Association 
of Medical Editors (WAME), and the Committee on Publication Ethics (COPE) for 
guidance on policies and procedures related to publication ethics. The policies for 
Diabetes Care have been adopted from those three advisory bodies and, where 
necessary, modified and tailored to meet the specific content, audiences, and aims of 
Diabetes Care. Comprehensive information related to the editorial and ethical 
policies of Diabetes Care can be found in Publication Policies and Procedures for 
Diabetes Care. The Association's Publications Policy Committee or Subcommittee 
on Ethical Scientific Publications will consider on a case-by-case basis policies that 
are not addressed in the policies document, which contains information related to the 
following topics:  
 
 Study Design 
 Originality and Prior Publication 





 Conflict of Interest 
 Data Access and Responsibility 
 Clinical Trials, Systematic Reviews, and Meta-Analyses 
 Plagiarism 
 Digital Image Manipulation 
 Responses to Possible Scientific Misconduct 
 Peer Review 
 Editorial Decisions 
 Prepublication of Accepted Articles 
 Reuse, Post-Prints, and Public Access 
 Errata 
 Media Embargos 
 Advertising 
 Supplements 
Frequently referenced segments of the document appear below.  
2.1. All human investigation must be conducted according to the principles 
expressed in the Declaration of Helsinki. All studies involving animals must state 
that guidelines for the use and care of laboratory animals of the authors' institution or 
the National Research Council or any national law were followed.  
Diabetes Care publishes only material that has not been published previously (either 
in print or electronically) and is not under consideration for publication elsewhere, 
with the exception of an abstract that is less than 400 words in length. Prior 
presentation of data (e.g., at a scientific meeting or via webcast) does not preclude 
publication in Diabetes Care, but should be disclosed in the Acknowledgments of the 
paper and in the author's comments to the editor upon manuscript submission. All 
submissions to the journal will be scanned for possible duplicate or prior publication 
using the CrossCheck/iThenticate plagiarism detection system 
(www.ithenticate.com/). Any article that eclipses a certain similarity threshold with 
another article will be closely reviewed by ADA. Authors who submit previously 
published work to the journal will be banned from submitting future manuscripts to 
the journal, and their funding body and/or institution will be notified.  
All contributions, including solicited articles and symposia, are critically reviewed 
by the editors and/or invited referees. Reviewers' comments are usually provided to 
the authors. The decision of the editors is final.  
2.2. Prepublication of accepted articles. To make new research readily available to 




before the print/online issue becomes available. These articles have been copyedited, 
proofread, and typeset but not yet author-approved or finalized and will appear in a 
future issue of Diabetes Care in print and online.  
Online Ahead of Print articles are citable by unique DOI (digital object identifier). 
DOIs for Diabetes Care articles begin with 10.2337, followed by the article number 
assigned when the manuscript was submitted online via the manuscript submission 
system. (e.g., 10.2337/dc11-1234)  
Example: Kohler C, Norton H, Farber K, Briggs E: How to cite a prepublished article 
in ADA journals. Diabetes Care 10.2337/dc11-1234  
2.3. Embargo dates. If you are interested in reporting on a Diabetes Care online-
ahead-of-print article, please visit 
http://care.diabetesjournals.org/misc/embargoinfo.pdf for specific instructions and 
conditions. Articles that were not prepublished are embargoed until they appear in an 
issue of Diabetes Care Online.  
2.4. NIH’s PubMed Central. Beginning with the July 2008 issue, the American 
Diabetes Association will deposit all final print articles accepted for publication in 
Diabetes Care in PubMed Central, a repository of peer-reviewed research maintained 
by the National Institutes of Health. ADA provides this service at no cost to authors. 
Articles are accessible on PubMed Central 12 months after the date of final 
publication in Diabetes Care. Authors may submit the accepted version of their 
manuscript to their funding body’s repository immediately upon acceptance.  
2.5 Clinical Trials. The International Committee of Medical Journal Editors 
(ICMJE) defines a clinical trial as “any research study that prospectively assigns 
human participants or groups of humans to one or more health-related interventions 
to evaluate the effects on health outcomes.” All clinical trials submitted to Diabetes 
Care must be registered with an approved ICMJE clinical trial registry 
(ClinicalTrials.gov, www.ISRCTN.org, www.actr.org.au, www.umin.ac.jp, and 
www.trialregister.nl), Diabetes Care accepts registration of clinical trials in any of 
the primary registers that participate in the WHO International Clinical Trial Registry 
Platform. Posting clinical trial results exceeding more than 500 words in the clinical 
trials registry is considered prior publication. Posting results in the form of a 
structured abstract (less than 500 words) or table is not considered prior publication. 
For definitions and further information, please see ICMJE’s clinical trials registration 
policy found in ICMJE's Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals. Please be sure to include the unique trial number and the name 
of the registry (e.g., NCTXXXXXXXX, ClinicalTrials.gov; or 
ISRCTNXXXXXXXX, www.ISRCTN.org) on the manuscript's title page.  
 
3. EDITORIAL OFFICE CONTACT INFORMATION 
Diabetes Care Editorial Office 
5110 Commerce Square Dr., Suite G 
Indianapolis, IN 46237  
phone: (317) 354-1508, ext 1782 fax: (317) 859-3592 
e-mail: diabetescare@diabetes.org 
Lyn Reynolds, Director, Editorial Office 
Shannon Potts and Jane Lucas, Peer Review Managers 
Rita Summers, Editorial Assistant 




4. FORMS AND REQUIREMENTS 
4.1. Each corresponding author, including those of letters, must read all three 
sections, check the appropriate boxes, sign, and be sure to include the names of all 
authors on the Manuscript Submission Form. The manuscript submission form 
addresses ADA’s policies on 1) originality and authorship, 2) copyright assignment, 
and 3) potential conflict of interest and addresses permission policies related to reuse 
and post prints. ADA will accept ICMJE's Uniform Disclosure Form for Potential 
Conflicts of Interest.  
It is recommended that manuscript submission forms be scanned and uploaded with 
the article files. If this is not possible, the corresponding author may fax (317-859-
3592) or email the completed form for all authors to the Editorial Office immediately 
after submission. Submissions will not be considered complete until the form has 
been received.  
The corresponding author designated on the title page will be the only person 
notified when proofs become available. (For further information, see Submitting a 
ManuscriptSection 7.1.1)  
4.2. Statement of Originality and Authorship. Diabetes Care subscribes to the 
requirements stated in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals that authorship implies substantial contributions to conception 
and design or analysis and interpretation of data and drafting of the article or critical 
revision for important intellectual content. The editor reserves the right to query 
authorship contribution.  
Writing groups: All collaborators should be listed at the end of the paper in the 
Acknowledgments (if no more than two or three short paragraphs) or in a separate 
supplemental online-only file.  
Author contribution paragraph: As of March 1, 2010, authors are required to 
include a paragraph in the Acknowledgments section listing each author’s 
contribution.  
Example: “C.K. researched data. L.R. wrote the manuscript and researched data. 
H.N. reviewed/edited the manuscript. V.S. contributed to the discussion and 
reviewed/edited the manuscript. N.B. researched data and contributed to discussion. 
V.G. wrote the manuscript.” 
Affiliations of those mentioned in the Acknowledgements section must also be 
noted. 
When citing “editorial assistance” or help provided by a colleague, authors are 
required to list the employer/institution with which that colleague is affiliated. 
Example: “The authors acknowledge the editorial assistance of Mark Smith, Global 
Informatics, Inc.”; “The authors thank Mark Smith, Global Informatics, Inc,. for help 
with preparing the manuscript.”  
4.3. Copyright Assignment. The American Diabetes Association holds the 
copyright on all material appearing in Diabetes Care, unless the content is produced 
by an employee of the U.S. government as part of the authors’ official duties. All 
authors must check the appropriate boxes and sign the Manuscript Submission Form, 
which transfers copyright to the ADA in accordance with the Copyright Revision Act 
of 1976. Please see the revised policy below for the statement of provenance and 
other conditions.  
4.3.1. Reuse. Authors are permitted to reuse portions of their ADA-copyrighted work 




ADA-copyrighted work for lecture or classroom purposes, provided that the proper 
citation and copyright information is given.  
4.3.2. Post-prints. Authors are permitted to submit the accepted version of their 
manuscript to their funding body or institution for inclusion in that funding body or 
institution’s database, archive, or repository, or to post the accepted version on their 
personal Web site. These manuscripts may be made freely accessible to the public 
upon acceptance, provided that the following two conditions are observed: 
First, post-prints must include the following statement of provenance and, once the 
final version has been published in the journal, a link to the final published version of 
the paper on the journal's Web site: 
This is an author-created, uncopyedited electronic version of an article accepted for 
publication in Diabetes Care. The American Diabetes Association (ADA), publisher 
of Diabetes Care, is not responsible for any errors or omissions in this version of the 
manuscript or any version derived from it by third parties. The definitive publisher-
authenticated version will be available in a future issue of Diabetes Care in print and 
online at http://care.diabetesjournals.org.  
Second, the version of the manuscript deposited or posted must be identical to the 
final accepted version, with the exception of the addition of the above statement and 
any changes necessary to correct errors. Authors may make changes to the posted 
version to correct mistakes or may issue an erratum at any time. However, the final 
published version of the manuscript may not be deposited, posted, or later substituted 
for the post-print.  
4.4. Conflict of Interest statement. All authors must read the ADA Policy 
Statement on Duality of Interest and check the appropriate box on the Manuscript 
Submission Form.  
In addition to completing the Manuscript Submission Form, all submitted papers 
must include a conflict-of-interest statement for all authors in the Acknowledgments 
section. If authors have no relevant conflict of interest to disclose, this should be 
indicated in the Acknowledgments section.  
Relevant conflict of interest (or lack thereof) should also be disclosed in the authors' 
comments to the editor during the submission process.  
4.5. Color Figure Approval. For a manuscript that contains color figures and is 
accepted for publication, the corresponding author must complete a color printing 
approval form. Forms are available online through the manuscript submission 
process. The cost of printing in color, to be borne by the author, is $490 U.S. per 
color figure. Color fees are based on individual figures as a whole, not by the part, 
i.e., A, B, C, etc. Authors will receive an invoice for publication fees when page 
proofs become available.  
 
5. MANUSCRIPT CATEGORIES 
See Section 6, Manuscript Format and Style, for detailed instructions on formatting 
documents.)  
5.1. Original Articles. Original Articles should be arranged in the following order: 
title page, structured abstract, introduction (no heading), “Research Design and 
Methods,” “Results,” “Conclusions,” “Acknowledgments,” “References,” tables, and 
figure legends.  




An abstract for an Original Article should not exceed 250 words. (This is not to be 
confused with abstracts submitted to the Annual Scientific Meeting, for which the 
word limit is higher.) The abstract must be self-contained and clear without reference 
to the text and should be written for a general journal readership. The abstract format 
should include four sections: “Objective” (the purpose or hypothesis of study), 
“Research Design and Methods” (the basic design, setting, number of participants 
and selection criteria, treatment or intervention, and methods of assessment), 
“Results” (significant data found), and “Conclusions” (the validity, limitations, and 
clinical applicability of the study and its results).  
As of July 1, 2011 the journal will follow new formatting guidelines for new 
submissions: The word count limit for Original Articles is a maximum of 4,000 
words. In addition, an original article is limited to a total combination of 4 tables and 
figures. Do not count words in tables, table legends, figure legends, title page, 
acknowledgments or references. References are limited to 40 citations. Exception to 
the word/table/figure/reference limit is rare.  
A conflict-of-interest statement for all authors must be included in the main 
document, following the text, in the Acknowledgments section. If authors have no 
relevant conflict of interest to disclose, it should be indicated in the 
Acknowledgments section.  
In the case of multicenter studies, authors should provide a list of participating 
investigators as an appendix to the paper. Papers will not be reviewed if this 
information is not included.  
Where appropriate, clinical and epidemiological studies should be analyzed to see 
if there is an effect of sex or ethnicity. If there is no effect, it should be stated as such 
in the “Results” section.  
Randomized Clinical Trial reporting: Authors of reports on randomized controlled 
trials are required to use the instructions and checklist in the Consolidated Standards 
of Reporting Trials (CONSORT) Statement. The instructions and checklist are 
designed to ensure that information pertinent to the trial is included in the study 
report. CONSORT information may be included in a supplemental online-only file 
so that it does not affect word count limitations.  
All clinical trials submitted to Diabetes Care for consideration of publication must 
be registered with a clinical trial registry approved by the International Committee of 
Medical Journal Editors (ICMJE). Please see Section 2.5 for more information.  
5.2. Brief Reports. A Brief Report can be formatted in one of two ways:  
 As a clinical observation/research report consisting of a structured abstract 
stating the study's objectives, followed by a short introduction (2–3 sentences) and 
four concise sections: "Research Design and Methods," "Results," "Conclusions," 
and "References." 
As a case report/case study consisting of a structured abstract, followed by a short 
introduction (2-3 sentences) and four sections: "History and Examination" describes 
the patient and provides a brief history; "Investigation" discusses the treatment 
findings and results; "Conclusions" summarizes the importance of the 




Neither format should exceed the allowed word count limit. (See Section 6, 
“Manuscript Format and Style,” for further information.)  
Brief Reports must include a structured abstract and may contain either one table 
or one figure, but not both.  
The format of title page, margins, text, table, figure, and font size for a Brief Report 
is the same as for an Original Article. Manuscripts should be double-spaced, written 
in Arial or Times New Roman 12-point font, and saved as a .doc, .txt, or .rtf file. The 
figure or table must follow guidelines provided in Sections 6.2 and 6.3 of 
“Manuscript Format and Style.”  
Brief Reports should include no more than 15 references.  
A structured abstract for a Brief Report should not exceed 150 words. The word 
limit for the main text is 1,000 words. Do not count words in the tables, figures, 
legends, the title page, acknowledgments, or references.  
The abstract must be self-contained and clear without reference to the text and should 
be written for a general journal readership. The abstract format should include four 
sections that reflect the section headings in the main text.  
A conflict-of-interest statement for all authors must be included in the main 
document, following the text, in the Acknowledgments section. If authors have no 
relevant conflict of interest to disclose, it should be indicated in the 
Acknowledgments section.  
5.3. Letters to the Editor. All Letters to the Editor are published only in the online 
version of Diabetes Care. Online-only letters are still listed in the table of contents of 
the print version and will be assigned an "E" page number, but they should be cited 
by use of their DOI (digital object identifier) rather than a page number (e.g., 
10.2337/dc07-XXXX).  
Letters do not have abstracts, should not exceed 500 words (excluding a maximum of 
5 references), and do not have tables or figures. As with all submissions, letters 
should be double-spaced and include a title page.  
 
A Comment Letter is a letter that comments on a recently published article and 
should include the cited paper as reference 1 in the reference list. It should be 
submitted within 3 months of the article’s printed publication. 
 
A Response Letter is an invited letter from the cited author that replies to the 
comment letter and must include the comment letter as reference 1 in the reference 
list.  
All letters require a signed Manuscript Submission Form from the authors. This must 
be faxed or uploaded to the manuscript submission system at the time of submission, 
without exception. A conflict-of-interest statement for all authors must be included in 
the main document, following the text, in the Acknowledgments section. If authors 
have no relevant conflict of interest to disclose, it should be indicated in the 
Acknowledgments section.  
5.4. Commentaries. Diabetes Care publishes Commentaries by invitation only. 
Commentaries normally accompany an original article or brief report and are invited 
by the editors. They should include a title page as with any submission, use 12-point 
Arial or Times New Roman font, and be double-spaced. A commentary is limited to 
1200 words and 25 references. It does not have an abstract. As with all submission, it 




including a conflict-of-interest statement for all authors in the main document. This 
should be placed at the end of the text, in the Acknowledgments section. If the 
authors have no relevant conflict of interest to declare, it should be indicated in the 
Acknowledgments section.  
5.5. Review Articles. Review Articles are by invitation or pre-approved submission. 
If you would like to submit an uninvited review, you must first submit a proposal to 
the editors.  
The proposal should include: 1) a detailed outline of the content of the proposed 
review; 2) a general idea of the amount of original literature to be summarized; and 
3) the background of the author(s) and a description of expertise in the area to be 
discussed in the review (or commentary). It is anticipated that the author(s) will have 
worked and published in the area covered by the review. The author should also state 
why he/she feels this particular review is suited for Diabetes Care and why the 
review would appeal to the readership.  
Lastly, the authors must disclose whether they propose to write the entire article 
themselves, whether they received any form of sponsorship or honorarium for the 
material, and whether a pharmaceutical company, or its representative, was involved 
in the funding or authorship. In addition, the authors must point out any potential 
conflict of interest with a company whose products will be discussed in the review.  
All proposals should be submitted by e-mail (as Word document attachments) to Lyn 
Reynolds in the Editorial Office (lreynolds@diabetes.org). Proposals must be 
received by the first Wednesday of the month in order for it to be scheduled for 
discussion at the next editorial meeting (second Monday of each month) by the 
Editor and Associate Editors. Review Articles submitted without prior approval or 
invitation will be returned. All Review Articles (whether invited or by query) are 
subject to peer review.  
Once approved, Review Articles are limited to 5000 words and 40-60 references. 
Review Articles do not have abstracts.  
5.6 Editorials. Editorials are solicited by the Editorial Committee. As with all 
submissions, an editorial must include a title page and authors must provide a signed 
Manuscript Submission Form. The word limit for an Editorial is 1,500 words, not 
including references. Editorials normally do not contain figures or tables. A conflict-
of-interest statement for all authors should be included at the end of the text or the 
Acknowledgments section, if one is included. Please label this section “Disclosure.” 
If the authors have no relevant conflict of interest to disclose, please indicate so in 
this section.  
5.7. Supplements. Supplements must be approved prior to submission. A proposal 
for a supplement should first be submitted to the Publications Department of the 
ADA (ckohler@diabetes.org) and must specify the following:  
 The name of the organization(s) sponsoring and funding the supplement (not 
merely the name of the public relations agency handling its publication). 
 If the supplement is based on a symposium, where and when the symposium 
was held and how the speakers and papers were selected. 




If the proposal is approved, it will be forwarded to the Editor of Diabetes Care. 
Initial approval by the ADA does not commit the Editor to accept a proposal in 
whole or part. All manuscripts are subject to the same peer review as other 
manuscripts in the journal.  
For complete instructions on submitting a supplement, please contact the Editorial 
Office.  
 
6. MANUSCRIPT FORMAT AND STYLE: Articles must be in clear and 
understandable English. Non-native English authors are encouraged to seek the 
assistance of an English-proficient colleague, or a communications agency such as 
“American Journal Experts”, to help improve the clarity and readability of a paper 
before it is submitted to the journal.  
6.1. The Main Document includes the title page, abstract, main text, 
acknowledgements, disclosure, figure legends, references, and tables. Please do not 
use headers, footers, or endnotes in your paper.  
6.1.1 Text Composition. Articles should be written in clear, concise English 
following the recommendations for scientific writing found in Scientific Style and 
Format, the Council of Science Editors (CSE) style manual (7th ed., 2006, Reston, 
VA, Council of Science Editors). All accepted manuscripts will be edited according 
to the CSE style manual and The Chicago Manual of Style (15th ed., 2003, Chicago, 
IL, The University of Chicago Press) by ADA professional publications staff. The 
authors are responsible for all statements made in their articles or editorials, 
including any editing changes made by staff. Proof pages should be read carefully.  
The designations type 1 diabetes and type 2 diabetes should be used when referring 
to the two major forms of diabetes. Abbreviations for diabetes, such as T2D for type 
2 diabetes, should not be used. The term diabetic should not be used as a noun.  
All manuscripts should be double-spaced, in Arial or Times New Roman 12-point 
font, and saved as a .doc, .txt, or .rtf file. In addition, please do not "lock" or "page 
protect" your document, and avoid using footnote and endnote functions.  
6.1.2. Abbreviations and Units. Abbreviations should be used only when necessary, 
e.g., for long chemical names (HEPES), procedures (ELISA), or terms used 
throughout the article. See the list of abbreviations that need not be defined; all 
others must be defined at first use. Abbreviate units of measure only when used with 
numbers. Abbreviations may be used in tables and figures. The CSE style manual 
contains lists of standard scientific abbreviations.  
Clinical laboratory values and units should be in Système International (SI) form. 
Kilocalories should be used rather than kilojoules. Glycated hemoglobin should be 
expressed as percentage of total and as standard deviation from mean control levels.  
6.1.3. Materials. Authors should provide the name and location (city and 
state/country) of the source for specified chemicals and other materials only if 
alternate sources are considered unsatisfactory.  
6.1.4. Title Page. Every manuscript, including Letters and Brief Reports, must have 
an accompanying title page. The title page should include the title; a short running 
title (less than 47 characters and spaces combined); the first name, middle initial, last 
name, and highest academic degree of each author; affiliation (in English) of each 
author during the study being reported; name, current address, telephone number, fax 
number, and e-mail address of the corresponding author; and the word count and 




The Main Document should be in Word document format (not as a PDF). This will 
allow our Editorial Office to verify the word count and our production staff to turn 
your paper (if accepted) into an article.  
6.1.5. Font. Text, including title and author names, should be in 12-point Arial or 
Times New Roman. Please avoid using boldface font. Text in tables should be no 
smaller than 10-point font.  
6.1.6. Margins. Margins should be 1" at the top and bottom and 1" on the left and 
right sides.  
6.1.7. Section Headers. Except for the Abstract, new sections should not begin on 
new pages. Each new section should immediately follow the end of the previous 
section. See Manuscript Categories for the proper headings.  
6.1.8. Abstract. Please see Section 5.1.1 of Manuscript Categories.  
6.1.9. Word Count Limit. Please see instructions for the individual type of article 
being submitted under section 5.1.2 of Manuscript Categories.  
6.1.10. Acknowledgments. The acknowledgments are located after the main text and 
before the reference list. Acknowledgments should contain the author contributions 
paragraph, brief statements of assistance, the guarantor's name (person(s) taking 
responsibility for the contents of the article), funding/financial support, and reference 
to prior publication of the study in abstract form, where applicable.  
6.1.11. References. The reference list should go at the end of the document, after the 
main text and acknowledgments (if applicable) and before the tables. Original 
Articles are limited to 40 references. Brief Reports are allowed 15 references. Letters 
are allowed 5 references. Review Articles are allowed 40-60 references and a Meta-
analysis should have no more than 40 references.  
Reference numbers in the text should appear in chronological order in normal type 
and in parentheses [e.g., “In the study by Norton et al. (23)...”]. Please do not use the 
footnote or endnote function to cite studies or create a reference list. A reference 
manager must have the ability to customize the display of references. For example, 
the reference application should have the option to list the references at the end of the 
paper, as opposed to listing the references as endnotes or footnotes at the bottom of 
each page, and should not embed the list in the text as a series of endnotes/footnotes. 
When using a reference manager (e.g., Thomson's EndNote Reference Program), 
don't forget to generate the list as a bibliography in a style suitable to Diabetes Care, 
and then save and submit as the final step to creating the references. Otherwise, 
references should be manually inserted.  
All authors must be listed by first initials and last name in each reference, and please 
provide inclusive page numbers. Journal titles should be abbreviated according to the 
National Library of Medicine’s List of Journals Indexed for Medline; for unlisted 
journals, please provide complete journal titles. Material in press may be cited, but 
copies of such material may be requested. Authors are responsible for the accuracy 
of the references. Click here for examples of how references should be formatted.  
6.1.12. Supplemental Data.(Original Articles only) Original Articles may contain 
online supplemental files if necessary. All supplementary data to appear online-only 
file should be combined in one document file (whenever possible) and uploaded 
separately during the submission process. It must be clearly labeled as “Online-Only 
Supplemental Material.” 
All online-only files are subject to review. Content of files submitted for online use 




submitting. In addition, supplemental Online-only materail must be referenced in the 
text at least once (e.g., “Supplemental Table S1”)  
Lists that include names of principal investigators or writing groups may be 
included in print as an Acknowledgement if no more than 150 words and should not 
be counted in the word count.  
Note: Please include a comment to the editor justifying the necessity of online 
supplemental materials for your Original Article. Allowance of online supplemental 
materials is at the discretion of the Editorial Committee.  
Do not put online supplemental material in the main document. Instead, it should be 
uploaded as a separate document.  
6.2. Tables. Each table should be inserted on a separate page at the end of the 
document with the table number, title, and legend indicated. Table legends should be 
inserted below the table and not be included inside the table. Tables should be 
created using Word and the "Insert Table" command. Please use Arial or Times New 
Roman font, no smaller than 10-point. Tables with internal divisions are not allowed 
(Tables 1A and B) and should be submitted as individual tables (Tables 1 and 2).  
6.3. Figures. Diabetes Care uses digital publishing methods throughout the journal 
production process. If your article is accepted, it will be published both in the printed 
journal and online. The following sections provide information on how to format 
your figures to ensure the best possible reproduction of your images.  
Size. Figures should be produced at the size they are to appear in the printed journal. 
Please make sure your figures will fit in one, two, or three columns in width. Multi-
paneled figures should be assembled in a layout that leaves the least amount of blank 
space.  
1 column = 13 picas wide, 2.2 in, 5.6 cm 
2 columns = 28 picas wide, 4.6 in, 11.7 cm 
3 columns = 41 picas, 6.8 in, 17.3 cm  
Font. At 100% size, fonts should be 8-10 points and used consistently throughout all 
figures.  
Text. Information on the axes should be succinct, using abbreviations where 
possible, and the label on the y-axis should read vertically, not horizontally. Key 
information should be placed in any available white space within the figure; if space 
is not available, the information should be placed in the legend. In general, figures 
with multiple parts should be marked A, B, C, etc., with a description of each panel 
included in the legend rather than on the figure.  
Line and bar graphs. Lines in graphs should be bold enough to be easily read after 
reduction, as should all symbols used in the figure. Data points are best marked with 
the following symbols, again assuring that they will be readily distinguishable after 
reduction: . In the figure legend, please use words rather than the 
symbols; e.g., "black circles = group 1; white squares = group 2; black bars = blood 
glucose; white bars = C-peptide." Bars should be black or white only, unless more 
than two datasets are being presented; additional bars should be drawn with clear 
bold hatch marks or stripes, not shades of gray.  
Line or bar graphs or flow charts with text should be created in black and white, not 
shades of gray, which are difficult to reproduce in even tones.  
Formatting digital figures files for print and online reproduction. To meet 
ADA’s quality standards for publication, it is important to submit digital art that 




will help to avoid delays in publication and maximize the quality of images, both 
online and in print. Please refer to ADA's Digital Art Guidelines when preparing 
your files. If you are unable to provide files that meet the specifications outlined in 
the Guidelines, you may submit your origial source files (files from the program in 
which they were originally created).  
Reproductions. If materials (e.g., figures and/or tables) are taken from other 
sources, the author must provide written permission for reproduction from the 
original publisher and author at the time of submission. In addition, the source should 
be cited at the end of the figure legend.  
Digital image manipulation. The American Diabetes Association has adopted the 
statement developed by the Journal of Cell Biology as its policy on the manipulation 
of digital images:  
“No specific feature within an image may be enhanced, obscured, moved, removed, 
or introduced. The grouping of images from different parts of the same gel, or from 
different gels, fields, or exposures must be made explicit by the arrangement of the 
figure (i.e., using dividing lines) and in the text of the figure legend. Adjustments of 
brightness, contrast, or color balance are acceptable if they are applied to the whole 
image and as long as they do not obscure, eliminate, or misrepresent any information 
present in the original, including backgrounds. Without any background information, 
it is not possible to see exactly how much of the original gel is actually shown. Non-
linear adjustments (e.g., changes to gamma settings) must be disclosed in the figure 
legend.”  
All digital images in manuscripts accepted for publication will be scanned using 
image forensics software for any indication of improper manipulation. Cases of 
questionable or inappropriate image alterations will be referred to the Association’s 
Subcommittee on Ethical Scientific Publications (ESP). The ESP may request the 
original data from the authors for comparison to the prepared figures. If the authors 
fail to provide the original data, the acceptance of the manuscript will be revoked. 
Cases of deliberate misrepresentation of data will result in revocation of acceptance, 
and will be reported to the corresponding author's home institution and/or funding 
agency as appropriate.  
For examples of what constitutes improper digital manipulation (as well as other 
forms of scientific misconduct), ADA encourages authors to refer to the 2006 
editorial by the Journal of Clinical Investigation titled “Stop Misbehaving!” In 
addition, authors are encouraged to refer to Adobe’s white paper on using Photoshop 
CS3 Extended in biomedical imaging. The paper provides useful information on 
maintaining image integrity, editing nondestructively, and the medical and scientific 
image workflow.  
 
7. SUBMITTING A MANUSCRIPT 
Please read the complete instructions for authors before submitting your manuscript 
to Diabetes Care via http://mc.manuscriptcentral.com/diabetescare.  
Your manuscript should be submitted under the user account of the designated 
corresponding author (the contact person listed on the title page of the manuscript). 
If the corresponding author does not have a user account, please follow the 






In the File Upload Center, you will be able to browse your computer for the files 
associated with your manuscript. When you upload each file, be sure to choose a 
designation from a pull-down menu that describes the file content (e.g., “Main 
Document,” “Figure,” “Table,” etc.). In addition, please make sure each file name 
clearly describes its content (e.g., “figure1.jpg,” “table2.doc,” “coverletter.doc,” 
etc.).  
The system automatically converts files to PDF files. Please do not upload PDF files 
except for signed Manuscript Submission Forms. Also, please do not upload zip files, 
docx or pptx files.  
A Instructions for submitting revised manuscript are included in the initial 
decision letter; revisions must meet all formatting requirements and word limits; no 
exceptions will be made. In addition, all signed manuscript forms must be faxed to 
the Editorial Office by the time the revision is submitted. If complete forms have not 
been received, it is likely that the revision will be unsubmitted. Receipt of forms may 
be verified by contacting Joan Garrett (jgarrett@diabetes.org).  
Revisions should be created by selecting “manuscripts with decisions” from the 
Author Center menu. Find the manuscript to be revised in the manuscript list. Click 
“create a revision” in the right column and a revision file will be created 
automatically. Revisions submitted under a new manuscript number will be returned 
to the author for proper submission.  
When revising your manuscript, please show corrections by track changes or a 
colored font to show additions and strikeout to show deleted text. Be sure to respond 
to all reviewer comments on the original submission.  
If you are submitting a revision, please include only the latest set of files. If you have 
updated a file, upload only the revised file. Do not include originally submitted files. 
Figures and tables must be uploaded with each version. Important: If it is a second 
or third revision, please indicate that the previously converted figures from the first 
revision are acceptable and may be used for print production if accepted.  
Once your text and image files are uploaded, please view these files to ensure they 
appear legibly and that all special characters have translated properly. Do not click 
"Submit Manuscript" until you are satisfied with the quality of the proofs. If you are 
having trouble uploading files, please click on the “Help” button in the top right 
corner of the manuscript submission screen or contact the Editorial Office for 
guidance.  
 
8. ACCEPTED MANUSCRIPTS 
8.1. Prepublication. For detailed information on publish-ahead-of-print articles, see 
Section 2.2 of Policies.  
8.2. Accepted manuscripts will be scheduled for publication as soon as possible.  
 
The designated corresponding author will receive notification of availability of page 
proofs by e-mail. Corrections should be returned within 24 hours of receipt of the 
proof. Failure to do so may delay the publication of the article.  
Correspondence concerning the copyediting and proofreading of accepted 
manuscripts should be addressed to Valentina Such, Editorial Manager, Diabetes 
Care, American Diabetes Association, 1701 North Beauregard St., Alexandria, VA 




Correspondence concerning the production of accepted articles and availability of 
page proofs should be addressed to Amy Gavin, Production Editor, American 
Diabetes Association, 1701 North Beauregard St., Alexandria, VA 22311; tel: 703-
299-2033; fax 703-253-4870; e-mail:agavin@diabetes.org.  
 
9. FINANCIAL OBLIGATIONS 
Page charges are assessed for Original Articles and Brief Reports to help defray costs 
of publication. The charge is $90 per page. As noted under Color Figure Approval 
(Section 4.5.), each color figure printed will incur a charge of $490. The 
corresponding author will receive via e-mail a pro forma invoice, as well as a reprint 
order form, when page proofs become available. Unless otherwise indicated, ADA 
will assume that the corresponding author is taking responsibility for payment.  
































































Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the 
title or the abstract 
(b) Provide in the abstract an informative and balanced summary 
of what was done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the 
investigation being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods of follow-
up 
Case-control study—Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. Give the 
rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants 
(b) Cohort study—For matched studies, give matching criteria and 
number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria 
and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 




8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control 
for confounding 
(b) Describe any methods used to examine subgroups and 
interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was 
addressed 
Case-control study—If applicable, explain how matching of cases 
and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods 
taking account of sampling strategy 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 




the study, completing follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of 
interest 
(c) Cohort study—Summarise follow-up time (eg, average and total 
amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures 
over time 
Case-control study—Report numbers in each exposure category, or 
summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary 
measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is 
based 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for 
exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 



































































































































NHS North of Scotland Research Ethics Committee Approval 
NRES Committees - North of Scotland  
Summerfield House 




Telephone: 01224 558474  
Facsimile: 01224 558609 
Email: nosres@nhs.net 
 
    
 
03 August 2011 
 
Miss Kirsty Matheson 









Dear Miss Matheson 
 
Study title: Emotional wellbeing following hospital admission for 
diabetic ketoacidosis 
REC reference: 11/AL/0339 
 
Thank you for your letter of 02 August 2011, responding to the Committee’s request for 
further information on the above research and submitting revised documentation. 
 
The further information was considered by the Scientific Officer. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start 
of the study (see "Conditions of the favourable opinion" below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host 
organisation prior to the start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.   
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 




The final list of documents reviewed and approved by the Committee is as follows: 
  
Document    Version   Date    
Covering Letter    22 July 2011  
Covering Letter    01 August 2011  
Investigator CV  n/a  06 June 2011  
Other: Care protocol  1  30 May 2011  
Other: CV - David Gillanders  n/a  02 March 2011  
Other: CV - Andrew Keen  n/a  06 June 2011  
Other: Participant covering letter time 2 3 & 4  1  30 May 2011  
Other: Participant follow up letter time 3 & 4  1  30 May 2011  
Other: GP Letter Time 1  1  30 May 2011  
Other: GP Letter Time 3  1  30 May 2011  
Other: GP Letter Time 4  1  30 May 2011  
Other: Attachment to questionnaires at Time 4  1  30 May 2011  
Other: Post-traumatic stress: key facts from the Royal College 
of Psychiatrists  
n/a  06 June 2011  
Other: Booklet - Depression  n/a  30 November 2009  
Other: Booklet - Health Psychology at the Diabetes Centre  n/a  30 November 2009  
Other: Booklet - Anxiety  n/a  30 November 2009  
Other: Recruitment Protocol  2  22 July 2011  
Other: Participant Reminder Letter  1  01 August 2011  
Participant Consent Form  2  22 July 2011  
Participant Information Sheet  3  01 August 2011  
Protocol  3  01 August 2011  
Questionnaire: HADS  1  30 May 2011  
Questionnaire: Impact of Event Scale - Revised  1  30 May 2011  
Questionnaire: PAID  1  30 May 2011  
Questionnaire: Acceptance & Action (AAQ-11)  1  30 May 2011  
Questionnaire: CFQ15  1  30 May 2011  
Questionnaire: NOVEL  1  30 May 2011  
REC application    09 June 2011  
Response to Request for Further Information    27 July 2011 
Response to Request for Further Information    02 August 2011  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 




The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light 




You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After 
Review  
 
11/AL/0339 Please quote this number on all correspondence 
 











Copy to: Miss Gemma Watson 



































Participant Information Sheet 
V3 – 01.08.11 
 
Emotional Wellbeing following admission for diabetic ketoacidodis 
You are being invited to participate in this project because you have recently 
experienced diabetic ketoacidosis.  
 
Before you decide, it is important for you to understand why the research is being 
carried out and what participating will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Please ask us 
if there is anything that is not clear or if you would like more information. Thank you 
for reading this.  
 
What is the background to the study? 
We know from research conducted over the past few decades that critical medical 
events can have a substantial impact on emotional wellbeing and this often goes 
undetected. Many of those who report clinically significant levels of emotional 
problems following traumatic events make a good recovery without the need for 
treatment. However, for a substantial minority, the negative emotional impact is 
lasting.  
The emotional wellbeing of people with diabetes is especially important. This is 
because emotional wellbeing is closely related to diabetes control and diabetes 
control largely dictates the longer-term health outcomes for people with diabetes.  
Diabetic ketoacidosis is a critical medical event, however little is known about its 
long term psychological consequences. Therefore, by taking measurements of 
psychological wellbeing and engagement with diabetes will supply health 
professionals with information to provide a more effective follow up care pathway 







What is the purpose of the study? 
The purpose of the study is to measure the emotional wellbeing of those with type 1 
diabetes after an admission to hospital for diabetic ketoacidosis. This will then 
inform future care provision and identify vulnerability factors for those who 
experience this complication. 
 
Why have I been chosen? 
You have recently experienced diabetic ketoacidosis and were admitted to hospital to 
manage this complication of type 1 diabetes. 
 
Do I have to take part? 
No.  It is up to you whether or not you take part.  If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part, you are still free to withdraw at any time without giving a 
reason for your withdrawal from the study. 
 
What will happen to me if I take part? 
You will be asked to complete a set of questionnaires at 3 different time points. 
Initially you will be provided the questionnaires during your current admission. You 
will be asked to complete and return them in the enclosed stamped address envelope 
within 1 week of receiving them. 
The same questionnaire shall be posted out to you one month, three months and six 
months later. Once you have completed these questionnaires, you will be asked to 
return them in the stamped address envelope provided. Should you not return the 
questionnaires within one week, the investigator shall send out a letter to remind you. 
You will also be asked your consent for the primary investigator to access your 








What do I have to do? 
If you would like to take part in the study, you can contact the researcher, Kirsty 
Matheson, who will provide you with a set of questionnaires to complete.  You will 
be asked to read and sign a consent form prior to commencement of the study.  The 
researcher will be present in your hospital to answer any questions about the study. 
 
What are the possible benefits of taking part? 
There are no direct benefits. However, you are being given the opportunity to 
contribute to the improved understanding of how diabetic ketoacidosis may impact 
the emotional wellbeing of those with type 1 diabetes. 
 
Will my taking part in this study be kept confidential? 
Yes.  All information collected from you during the course of this study will be kept 
strictly confidential.  Participants will be assigned a participant number and 
individual data will not be reported in outputs from the study. 
 
What will happen to the results of the research study? 
The results of the study will be used to evaluate emotional wellbeing of those with 
type 1 diabetes post diabetic ketoacidosis.  Results will be submitted to a diabetes 
care journal for publication. 
 
Who has reviewed the study? 
The study has been reviewed by NRES Committees- North of Scotland.  
 
Contact for further information 
If you have any questions about the study please contact Kirsty Matheson, Trainee 









If you wish to contact an independent about research in general or have any cause to 
complain regarding this project please contact: Dr. Heather Wilkinson, Research 
Director, School of Health in Social Science, University of Edinburgh, Teviot Place, 
Edinburgh, EH8 9AG. Tel: 0131 651 3969.  
 
To report problems with the study 
For enquiries about complaints or to make a complaint about the study please 
contact: 






Telephone: 01224 556447 



























Participant Consent Form 
11/AL/0339 
Patient Identification Number for this trial:  
 
CONSENT FORM 
V 2                                                           22.07.11 
 
Title of Project: Emotional wellbeing following hospital admission for diabetic 
ketoacidosis 
 
Name of Researcher: Kirsty Matheson 
 
 
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated 01.08.11 
(version 3) for the above study. I have had the opportunity to consider the 
 information, ask questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at  




3. I understand that relevant sections of my medical notes and data collected 
 during the study, may be looked at by individuals from regulatory authorities or 
 from the NHS Trust, where it is relevant to my taking part in this research. I give 
 permission for these individuals to have access to my records.  
 
 
4. I agree to the primary investigator accessing medical records and  
routinely collected diabetes related data from the SCI-DC database. 
 
 













_________________________ ___________ ________________________ 
 
Name of Patient      Date    Signature  
 
_________________________ ____________ ________________________ 
 
Name of Person Taking Consent   Date    Signature  
 
 





























Letter to GP and diabetes team regarding patient participation 
 
 
11/AL/0339 version 1 30/05/11 























Re: Participant Name (Date of Birth) Address, CHI 
 
 
Your patient has agreed to take part in the following study “Emotional wellbeing following hospital 
admission for diabetic ketoacidosis”. A copy of the patient information sheet is enclosed for your 
information. As part of the study your patient may be identified as having significant levels of depression 
and/or anxiety and/ or post traumatic stress disorder symptoms. If your patient scores clinically significant 
for the aforementioned domains at 3 month follow up, I shall notify you.  
 
If you require any further information please contact Kirsty Matheson, Trainee Clinical Psychologist by 







    
 
Kirsty Matheson      Dr Andrew Keen       




CC:   ARI Notes 
Diabetes Medical Notes 

























Three month follow-up patient letter if scoring at clinical levels for anxiety/ 
depression/ PTSD  
 
 
11/AL/0339 version 1 30/05/11 
Participant follow up letter follow-up 
letter if clinical levels 
 
 


















Thank you very much for recently completing the set of questionnaires for the study 
“Emotional wellbeing following hospital admission for diabetic ketoacidosis”. 
 
After scoring up the inventories you kindly filled out, your scores indicate that you are scoring 
at clinical significance for anxiety/ depression/ post traumatic stress disorder symptoms (to 
delete as appropriate).  At this time we would advise you to contact your General Practitioner 
(GP) to discuss this further.  We shall also notify your GP of your self-report scores.  
 
Please find enclosed a leaflet about anxiety/ depression/ post traumatic stress disorder 
symptoms  (to delete as appropriate) as well as a leaflet about the psychology service at the 
diabetes centre (with contact details if you wish to refer yourself).  
 
I appreciate that this letter may be of surprise to you and therefore please do not hesitate to 
contact me should you require any further information, email: kirsty.matheson@nhs.net or 










Kirsty Matheson      Dr Andrew Keen       
Trainee Clinical Psychologist    Consultant Health Psychologist  
 
 
























Three month follow-up letter to GP if patient scoring at clinical levels for anxiety/ 
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Re: Participant Name (Date of Birth) Address, CHI 
 
 
I wrote to you on the (date) to inform you that your patient had enrolled in the following study 
“Emotional wellbeing following hospital admission for diabetic ketoacidosis”.  
At three months follow-up your patient has scored at clinical significance for anxiety/ depression/ 
post traumatic stress disorder symptoms (delete as appropriate).  
I have informed your patient that they have scored at clinically significant levels and advised 
them to contact you.  In addition, I sent your patient  an information leaflet about anxiety/ 
depression/ post traumatic stress disorder symptoms (delete as appropriate)  as well as 
information about the local diabetes psychology service (which has details for self-referral). 
 
If you require any further information please contact Kirsty Matheson, Trainee Clinical 






    
 
Kirsty Matheson      Dr Andrew Keen       




CC:   ARI Notes 
Diabetes Medical Notes 
Enclosed:  Patient letter 
  Anxiety/ depression/ PTSD psycho-education 
























Hospital Anxiety and Depression Scale (HADS) 
 
This questionnaire will help you to let us know how you are. Read each item and tick the response that 
comes closest to how you have felt in the last week. Don't take too long over your replies, your immediate 





. I feel tense or `wound up' 
 
3 Most of the time  
2  A lot of the time  
1  From time to time 




. I still enjoy the things I used to enjoy 
 
 
0 Definitely as much 
1 Not quite so much 
2 Only a little  




. I get a sort of frightened feeling as if 
    something awful is about to happen 
 
3 Very definitely and quite badly  
2 Yes, but not too badly  
1 A little, but it doesn't worry me  




. I can laugh and see the funny side of things 
 
0 As much as I always could 
1 Not quite so much now 
2 Definitely not so much now  




. Worrying thoughts go through my mind 
 
3 A great deal of the time  
2 A lot of the time  
1 From time to time but not too often. 




. I feel cheerful 
 
3 Not at all  
2 Not often  
1 Sometimes  




. I can sit at ease and feel relaxed 
 
 
0 Definitely  
1 Usually  
2 Not often  





. I feel as if I am slowed down 
 
3 Nearly all the time 
2 Very often 
1 Sometimes  




. I get a sort of frightened feeling like 
    `butterflies' in the stomach 
 
0 Not at all  
1 Occasionally 
2 Quite often 




. I have lost interest in my appearance 
 
 
3 Definitely  
2 I don't take so much care as I should  
1 I may not take quite as much care  




. I feel restless as if I have to be on the move 
 
3 Very much indeed  
2 Quite a lot 
1 Not very much 




. I look forward with enjoyment to things 
 
0 As much as ever I did 
1 Rather less than I used to  
2 Definitely less than I used to  




. I get sudden feelings of panic 
 
3 Very often indeed  
2 Quite often 
1 Not very often 




. I can enjoy a good book or radio or TV  
      programme 
 
0 Often  
1 Sometimes  
2 Not often  
3 Very seldom 
HADS 
 A: 0-7 8-10 >10 
 



























Impact of Events Scale - Revised (IES-R) 
11/AL/0339 version 1 30/05/11 
IMPACT OF EVENT SCALE – REVISED 
 
Below is a list of difficulties people sometimes have after stressful life events. Please read 
each item, and then indicate how distressing each difficulty has been for you DURING THE 
PAST SEVEN DAYS with respect to your recent hospital admission for diabetic 
ketoacidosis, which occurred on ______________.  
 
How much were you distressed or bothered by these difficulties? 
 
 0 = Not at all; 1 = A little bit; 2 = Moderately; 3 = Quite a bit; 4 = Extremely. 
 
1. Any reminder brought back feelings about it.    ____         
2. I had trouble staying asleep.       ____         
3. Other things kept making me think about it.     ____         
4. I felt irritable and angry.       ____         
5. I avoided letting myself get upset when I thought about it or  
was reminded of it.        ____         
6. I thought about it when I didn’t mean to.     ____         
7. I felt as if it hadn’t happened or wasn’t real.    ____         
8. I stayed away from reminders of it.      ____         
9. Pictures about it popped into my mind.     ____         
10. I was jumpy and easily startled.     ____         
11. I tried not to think about it.       ____         
12. I was aware that I still had a lot of feelings about it, but I  
didn’t deal with them.        ____         
13. My feelings about it were kind of numb.     ____         
14. I found myself acting or feeling like I was back at that time.   ____      
15. I had trouble falling asleep.       ____         
16. I had waves of strong feelings about it.     ____         
17. I tried to remove it from my memory.     ____         
18. I had trouble concentrating.       ____         
19. Reminders of it caused me to have physical reactions, such  
11/AL/0339 version 1 30/05/11 
as sweating, trouble breathing, nausea, or a pounding heart.   ____         
20. I had dreams about it.       ____         
21. I felt watchful and on-guard.      ____         
22. I tried not to talk about it.       ____         
 
























Problem Areas in Diabetes (PAID) 
11/AL/0339 version 1 30/05/11 
 
 
Which of the following diabetes issues are currently problems for you? Circle the number that gives the best 





1. Not having clear and concrete goals for your diabetes care? 
 
2. Feeling discouraged with your diabetes treatment plan? 
 
3. Feeling scared when you think about living with diabetes? 
 
4. Uncomfortable social situations related to your diabetes (e.g., 
people telling you what to eat)? 
 
5. Feelings of deprivation regarding food and meals? 
 
6. Feeling depressed when you think of living diabetes? 
 
7. Not knowing if your mood or feelings are due to your diabetes? 
 
8. Feeling overwhelmed by your diabetes? 
 
9. Worrying about low blood sugar reactions? 
 
10. Feeling angry when you think about living with diabetes? 
 
11. Feeling constantly concerned about food and eating? 
 
12. Worrying about the future and the possibility of serious 
complications? 
 
13. Feelings of guilt or anxiety when you get off track with your 
diabetes management? 
 
14. Not accepting your diabetes? 
 
15. Feeling unsatisfied with your diabetes physician? 
 
16. Feeling that diabetes is taking up too much of your mental & 
physical energy every day? 
 
17. Feeling alone with your diabetes? 
 
18. Feeling that your friends and family are not supportive of your 
diabetes management efforts? 
 
19. Coping with complications of diabetes? 
 
20. Feeling burned out by the constant effort needed to manage 
diabetes? 
 Not a          Minor         Somewhat    Serious 
      Problem      Problem  Serious   Problem 

























System of care should participant score at clinical levels for anxiety/ depression/ 
PTSD 




From the literature (e.g. NICE PTSD guidelines) one would expect clinically 
significant levels of anxiety and/or depression and/or post traumatic stress 
disorder symptoms at admission and 1 month follow up. However, if at 3 
month follow up participants are self-reporting clinically significant levels of 
anxiety and/ or depression and/ or post traumatic stress disorder symptoms 














At 3 month follow-up 
Primary investigator to score anxiety, depression and post traumatic 
stress symptoms from inventories 
If clinically significant levels of anxiety and/or 
depression and/or post traumatic stress 
disorder symptoms 
 





Inform patient  of anxiety and/ or 
depression and/ or post traumatic 
stress disorder symptoms and to seek 
advice from GP. 
 
With letter enclose anxiety and/ or 
depression and/or post traumatic 
stress disorder symptoms leaflet as 
well as NHS Grampian Diabetes in 
Psychology leaflet . 
 
Inform GP and Diabetologist 
that participant is scoring at clinical 
significance for anxiety and/ or 
depression and/or post traumatic 
stress disorder at 3 month follow up 



































Miss Kirsty Matheson 







  Your Ref [your ref]  
  Our Ref 2011GD002 
 
  Enquiries to  
  Extension 51121 
  Direct Line 01224 551121 




Dear Miss Matheson 
 
Management Permission for Non-Commercial Research 
 
REC Ref:  11/AL/0339 
Project title:  Emotional wellbeing following hospital admission for diabetic  
   ketoacidosis 
 
Thank you very much for sending all relevant documentation.  I am pleased to confirm that the 
project is now registered with the NHS Grampian Research & Development Office.  The project 
now has R & D Management Permission to proceed locally.  This is based on the documents 
received from yourself and the relevant Approvals being in place. 
 
All research with an NHS element is subject to the Research Governance Framework for Health 
and Community Care (2006, 2nd edition), and as Chief or Principal Investigator you should be fully 
committed to your responsibilities associated with this. 
 
It is particularly important that you inform us when the study terminates. 
 
The R&D Office must be notified immediately and any relevant documents forwarded to us if any of 
the following occur: 
 
 A change of Principal Investigator, Chief Investigator or any additional research personnel 
 Premature project termination 
 Any amendments – substantial or non-substantial (particularly a study extension) 
 Any change to funding or any additional funding  
NHSG-RD-DOC-019 – V3.1 – R&D Management Permission Letter (Non CTIMP) 
 
We hope the project goes well, and if you need any help or advice relating to your R&D 
Management Permission, please do not hesitate to contact the office. 
 
 
Yours sincerely 
 
 
 
 
Susan Ridge 
Non-Commercial Manager 
 
 
 
 
